CIRCLE Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
CIRCLE Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Justin Van Roy | A2 Labs | jvanroy@a2labs.com | Arlington, VA | Our research focuses on turning government R&D into deployable products, spanning digital biomarkers from raw smartphone sensors, trustworthy autonomy via uncertainty quantification and anomaly detection under degraded sensing, and multimodal detection using noisy visual, acoustic, and RF data (including spiking neural networks). We also build scalable AI systems across ML, RL, LLMs, and agentic infrastructure for SBIR/STTR and DARPA programs. | We seek clinical and biological partners to integrate our uncertainty-quantified AI and digital twin infrastructure approaches into a complete CIRCLE solution. Our goal is to pair our expertise in anomaly detection under degraded sensing and agentic ML infrastructure with clinical data to deliver a robust, FDA compliant system. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Justin Van Roy | A 2 Labs | jvanroy@a2labs.com | Arlington, VA | Our research focuses on turning government R&D into deployable products, spanning digital biomarkers from raw smartphone sensors, trustworthy autonomy via uncertainty quantification and anomaly detection under degraded sensing, and multimodal detection using noisy visual, acoustic, and RF data (including spiking neural networks). We also build scalable AI systems across ML, RL, LLMs, and agentic infrastructure for SBIR/STTR and DARPA programs. | We seek clinical and biological partners to integrate our uncertainty-quantified AI and digital twin infrastructure approaches into a complete CIRCLE solution. Our goal is to pair our expertise in anomaly detection under degraded sensing and agentic ML infrastructure with clinical data to deliver a robust, FDA compliant system. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Farhan Khodaee | Absentia Labs | farhan@absentia.bio | Boston, MA | Absentia Labs is a frontier AIxBio startup developing advanced AI foundation models and digital twin platforms for biology. Founded by MIT engineers, the company builds and validates models that integrate biological and clinical data to simulate cellular and immune system response. Our technology enables creation of patient-specific digital twins and virtual cell models capable of predicting disease trajectory, identifying therapeutic control points and optimizing drug response. | We are looking for partners with expertise in clinical care medicine, immunology and preclinical model creating and validation, as well as groups generating high-resolution patient-cell-based immune datasets. We are also interested in working with diagnosis and therapeutic companies to integrate digital twin virtual cell models into their workflows | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform |
| Joseph Cohn | ACCELINT | joseph.cohn@soartech.com | Ann Arbor, MI | SoarTech develops supervisory control for high-consequence, dynamic systems using agentic AI, causal state reasoning, & uncertainty-aware decision support. Our work spans distributed autonomous system control, interpretable causal modeling, & clinical decision support. We deliver supervisory systems in safety-critical domains, including complex healthcare environments. For TA2, we will build the supervisory layer that, integrates measurement, modeling & intervention under real-world constraints. | We seek TA1 and TA3 collaborators with expertise in inflammatory biology, ICU-to-post-ICU transitions, and organ failure progression to co-develop mechanistically grounded trajectory state models. Partners should include TA1 innovators generating high-resolution inflammatory measurements and TA3 teams advancing actionable modulation strategies. Clinical validation sites and longitudinal datasets are critical to operationalize a supervisory Model-layer architecture | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Alexander Yoshikawa | Adaptyx Biosciences | ay@adaptyx.bio | Menlo Park, CA | Adaptyx has developed a wearable, multi-analyte molecular monitoring platform for continuous, real-time measurement of biomarker panels from dermal interstitial fluid. The system has been demonstrated in humans across multiple analytes and enables high-frequency tracking of metabolites, electrolytes, cytokines, kynurenine metabolites, and drugs. The platform is scalable and supports rapid de novo sensor development for new targets. | Adaptyx seeks ICU clinical partners, systems immunology and digital twin modeling teams, and groups developing immune modulation strategies. Ideal collaborators provide access to critically ill patient cohorts, clinical trial infrastructure, and data integration expertise. We aim to contribute continuous, multiplex molecular data to enable real-time immune trajectory modeling and treatment response monitoring. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Mike Fisher | Alden Scientific | mike@aldenscientific.com | Cambridge, MA | Alden Scientific measures virtually all human biology and uses machine learning to capture the highest resolution picture of human health, providing unique insights and future health state predictions. Our proprietary AI technology integrates and analyzes complex multi-omic data - genetic, proteomic, epigenetic, immunomic and beyond - to reveal what drives health and longevity at the individual level. | We have a unique platform for studying autoantibodies and the B Cell side of the immune system and would be interested in talking to companies studying T Cell responses. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Eva Maria Janerus | Alden Scientific | evamaria@aldenscientific.com | Cambridge, MA | Alden Scientific Immune (formerly Oncimmune) offers next-generation autoantibody profiling which can be integrated into Alden Scientific's multi-omic AI platform alongside proteomics and other 'omics. Our immunoINSIGHTS 2K platform includes a verified panel of 1,920 human-disease-relevant antigens and the largest reference data set of 10,000+ immune profiles across diseases and demographics. We're focused on early detection / risk stratification, and discovering novel targets and pathways. | Researchers and partners with large cohorts looking for immune profiling and AI partnering. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Alan Fine | Alentic Microscience Inc. | afine@alentic.com | 1344 Summer St., Halifax, Nova Scotia, Canada B3H0A8 | Alentic's handheld devices let anyone run a wide range of diagnostic tests -- CBC, immunoassay, serology, immunocytometry and more -- in minutes on a pinprick of blood or other liquid, making these important tests easily and economically available wherever and whenever needed. Current research focus areas include AI-based integration of multiple simultaneous analyses on a single droplet of blood to yield earlier, more sensitive and specific detection of critical conditions such as sepsis. | We are looking for partners with complementary capabilities (e.g., biomarker antibody, electrochemistry, and consumable production at scale; established distribution, sales and service). | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Jason Rodriguez | Applied Research Associates, Inc | jrodriguez@ara.com | Raleigh, NC | ARA specializes in mechanistic and data-driven approaches to physiological modeling. We have developed mechanistic immuno-inflammatory response models, including innate response of wound healing, full-body response during sepsis, and molecular/cellular interactions in response to injuries and biological pathogens. Our BioGears Physiology Platform includes a modeling framework ideal for generating digital twins and incorporating high fidelity models of critical illness and interventions. | We are looking to join a Type A response as a TA2 lead. | TA2: Model - Digital Twin Generator |
| Ginu Unnikrishnan | Applied Research Associates, Inc. | gunnikrishnan@ara.com | Arlington, Virginia, VA | ARA specializes in mechanistic and data-driven approaches to physiological modeling. We have developed mechanistic immuno-inflammatory response models, including innate response of wound healing, full-body response during sepsis, and molecular/cellular interactions in response to injuries and biological pathogens. Our BioGears Physiology Platform includes a modeling framework ideal for generating digital twins and incorporating high fidelity models of critical illness and interventions. | We are looking to join a Type A response as a TA2 lead. | TA2: Model - Digital Twin Generator |
| Graeham Douglas | AreteMedical | gdouglas@aretemedtech.com | Cambridge UK | Measurement and data platform for lung inflammation, narrowing, stiffening | Clinical validation, data collection. Complementary data/signal sources | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Matthew Peet | Arizona State University | mpeet@asu.edu | Tempe, AZ | Dynamic modeling of helper-regulatory immune response. Mapping biomarkers to immune state estimates. Parameter identification in immune models using sparse, irregular, and noisy time-series data. | Collaborators to design experimental frameworks for data-based identification of immune state. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Tejasvi Parupudi | Arizona State University | tejasviparupudi@gmail.com | Tempe, AZ | My researc focus is on identifying digital biomarkers from ICU-scale clinical data to detect and predict critical illness transitions, including hemorrhagic transformation following ischemic stroke. Using MIMIC III and similar datasets, I integrate lab values, physiologic signals, medications and clinical text to construct data driven immune and physiologic descriptors. This work advances computatinal phenotyping, risk modeling and early warning frameworks that support digital twin development. | I am seeking interdisciplinary partners with expertise in computational modeling, translational imunology, and regulatory-grade digital health systems. Idela collaborators would bring strengths in mechanistic modeling, digital twin development, clinical NLP, and prospective validation in ICU settings. Partnerships with groups experienced in FDA compliant platform development, multicenter clinical trials, and scalable data infrastructure are particularly valuable. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Benjamin Gaston | Atelerix Life Sciences and Indiana University | begaston@iu.edu | Indianapolis, IN | We have data supporting three paradigm-shifting ideas 1. A respiratory stimulant that overcomes drug-induced respiratory depression; therer is no respiraotry stimulant in use in the ICU , aside from caffeine in the NICU. 2. An inhalational anti-inflammatory agent that human airway epithelial viral replication (for RSV, SARS CoV2 and human metapneumovirus) that raises epithelial pH: itis well-tolerated in humans. A non-invasive device for measuring tissue thiol-bound NO in the ICU | Partners in drug and device development through to IND's. | AP3: Critical Illness Clinical Trials Platform |
| George (Bill) Jackson | Base Pair Biotechnologies, Inc. | bill.jackson@basepairbio.com | Houston, TX | Base Pair Biotechnologies develops custom DNA and RNA aptamers for diagnostics, biosensors, and therapeutic targeting. The company specializes in multiplex discovery of affinity reagents against multiple protein targets simultaneously. These reagents can enable multiplex measurement of immune biomarkers (e.g., cytokines and complement factors) and can be integrated into biosensor platforms or therapeutic targeting approaches relevant to immune dysregulation in critical illness. | We seek collaborators developing immune monitoring platforms, biosensors, or therapeutic strategies for critical illness. BasePair can contribute aptamer panels for multiplex measurement of inflammatory and immune markers in a variety of sample matrices – whole blood, serum/plasma, urine, saliva, etc. We also support therapeutic aptamer campaigns for immune modulation. We are particularly interested in teams pursuing TA1 measurement systems or TA3 immune intervention strategies. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer, AP1: Critical Illness Clinical Data & Analysis Platform |
| Timothy Chou | BevelCloud | tim@bevelcloud.io | Marina del ey, CA | A real-time, privacy-preserving distributed AI cloud infrastructure to enable Disease and Trial-precise AI Agents | AI applications/agents which would benefit from learning on large data sets, while preserving privacy, with the ability to deploy to the point of care. | AP3: Critical Illness Clinical Trials Platform |
| Susan Levinson | BioAegis Therapeutics Inc. | slevinson@bioaegistx.com | North Brunswick, NJ | Normal human protein biomarker of excess inflammation and therapeutic in 600 subject clinical study in critical care/ARDS. | open | AP1: Critical Illness Clinical Data & Analysis Platform, TA1: Measure - Dynamic Immune Descriptor |
| Brian Kelly | Biolinq Incorporated | briankellymd@gmail.com | San Diego, CA | Biolinq focuses on the development of painless, continuous intradermal sensors that can measure multiple analytes important to the immune response in critical illness. | Partners in need of a continuous sensing platform for multiple analytes. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Max Perelman | Biomeme, Inc. | max@biomeme.com | Philadelphia, PA | Biomeme provides a handheld, battery-powered CLIA Waivable POC platform for detection of up to 48 DNA/RNA targets from peripheral and capillary (finger stick) whole blood in <10 minutes. The system can directly connect to LIMS/EMR/EHR through its internal BLW/WiFi chip. Our current research focus is on development of rapid mRNA-based diagnostics for deployment onto our POC platform. | We are a TA1 sub-performer looking to team with an Integrator/Program Lead submitting a Type A proposal. | TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| Paulo Garcia | BLASTID | paulo@blastid.life | Boston, MA | BLASTID is developing SPLENDID, an IVD platform for ultra-rapid isolation and single-cell characterization of rare cell populations directly from whole blood. Combining advanced microfluidics with AI-powered image analysis, SPLENDID delivers pathogen ID within minutes to support clinical decisions during the critical treatment window in bloodstream infections. The platform will expand to profile host cells, to provide holistic information and overcome delays in diagnosing autoimmune disorders. | We welcome conversations with groups bringing complementary expertise in TA2 digital twin modeling and TA3 immunomodulatory intervention and adaptive regulatory strategy. Clinical ICU partners with access to diverse critical illness populations are also of interest. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Ivan Caffrey | BlueBridge Technologies | ivancaffrey@bluebridgetech.com | International HQ, Dublin Ireland; US HQ, Texas, TX | Regulatory-engineering partner for CIRCLE digital twins & ICU platforms. We stand up the design-control spine (requirements→tests→evidence) so TA outputs are AP-ready: Table-3 handoff packs for AP1/AP2/AP3, audit trails for IV&V, and Phase I FDA outreach/planning → Phase III filing readiness. UL-certified ISO 13485/14971/IEC 62304. | We seek TA teams building sensing (TA1), mechanistic digital twins (TA2) and modulation studies (TA3) who want to win down-selects by being IV&V-ready. Ideal partners value disciplined milestone/metric evidence, rapid packaging of AP-requested data/code/models, and early alignment to AP2’s FDA-requirements review + compliance verification. | AP2: FDA-compliant Digital Twin Platform |
| Vangelis Simeonidis | Buck Institute for Research on Aging | vsimeonidis@buckinstitute.org | Novato, CA | The Buck Institute is dedicated to combating age-related diseases through multidisciplinary science. The Yurkovich Lab utilizes systems biology and multiscale AI to develop mechanistic digital twins that predict patient trajectories and simulate precision interventions. The Verdin Lab provides biological ground truth on innate/adaptive immune-metabolic signaling and age-related chronic inflammation to identify therapeutic control points. | We seek clinical partners (ICUs, Level 1 Trauma Centers, etc.) to provide high-frequency, longitudinal patient data and validate digital twin trajectories. We are looking for measure (TA1) experts in near-bedside, tissue-specific biosensors to fuel our mechanistic models. Additionally, we welcome commercial partners with experience in FDA Regulatory filings to accelerate Phase II/III transition and secure required cost-sharing. | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Robert Rae | CAP | rrae@cap.org | Northfield, IL | We are focused on the standardization and semantic interoperability of laboratory and pathology test order and result data. We have been a partner in the SHIELD initiative to drive change in this space. The absence of laboratory semantic interoperability or the ability of two or more systems to exchange and analyze information the same way for in vitro diagnostic (IVD) devices - has been a significant impediment to the continuity of patient care, research, and overall public health | We are not looking to be prime on this initiative, we are looking to support the interoperability, standardization and quality of lab and pathology data from an immunological perspective. | AP1: Critical Illness Clinical Data & Analysis Platform |
| Hongzhang He | Captis Diagnostics | simonhe@captisdx.com | Pittsburgh, PA | We developed blood-based dynamic immune profiling from extracellular vesicles. Our technology detect at least 250 dynamic immune profiling markers detected in plasma extracellular vesicles (EVs). These markers encompass the full spectrum of immune responses including innate immunity (TLRs, complement, inflammasome), adaptive immunity (T cells, B cells, NK cells), antigen presentation (HLA/MHC), and immune regulation (checkpoints, cytokines, chemokines). | We are looking for clinical data analysis platform and clinical trial collaborators. | TA1: Measure - Dynamic Immune Descriptor |
| Kislaya Kunjan | Cascade Metrix, Inc. | kkunjan@cascademetrix.com | Indianapolis, IN | Cascade Metrix develops a real-time, patient-connected multiplex whole-blood biomarker platform for critical care. The system enables automated, high-frequency measurement of metabolic and physiologic markers (initially glucose, lactate, hemoglobin, oxygen saturation) to generate longitudinal ICU time-series datasets in sepsis and trauma. The platform is expandable to incorporate immune and inflammatory biomarkers for systems-level modeling of critical illness. | We seek systems immunology and computational modeling (TA2) collaborators to integrate high-frequency physiologic and immune biomarker time-series data into validated digital twin frameworks. We also welcome partnerships with immunomodulatory (TA3) investigators. With ICU deployment access, we aim to support model development and translational validation in real-world critical care settings. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Kislaya Kunjan | Cascade Metrix, Inc. | kkunjan@cascademetrix.com | Indianapolis, IN | Cascade Metrix develops a real-time, patient-connected multiplex biomarker platform for critical care. The system enables automated, high-frequency whole-blood measurement of metabolic and physiologic markers (initially glucose, lactate, hemoglobin, oxygen saturation) to generate longitudinal ICU time-series datasets in sepsis and trauma. The platform is expandable to incorporate immune and inflammatory biomarkers for systems-level modeling of critical illness. | We seek systems immunology and computational modeling (TA2) collaborators to integrate high-frequency physiologic and immune biomarker time-series data into validated digital twin frameworks. We also welcome partnerships with immunomodulatory (TA3) investigators. With ICU deployment access, we aim to support model development and translational validation in real-world critical care environments. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Kenneth Remy | Case Western Reserve University | kenneth.remy@uhhospitals.org | Cleveland, OH | Our organization integrates AI-driven machine learning with advanced immune endotyping across sepsis, cancer, and critical illness. Using functional assays and multi-omic profiling, we define immune states in real time to identify actionable control points and enable precision deployment of targeted immunotherapies. | We seek partners to deploy and validate these endotyping platforms across diverse clinical settings, enabling predictive enrichment and scalable implementation. Ideal collaborators will support multicenter data integration, rapid clinical trial enrollment, and evaluation of targeted immunomodulatory therapies. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Luke Spaulding | Centauri Labs | lukespaulding@outlook.com | Tulsa, OK | We are currently developing a patient-centric ecosystem for immunological health, serving as a "Total Human System" ledger. Our research focuses on high-fidelity data acquisition via a voice-first AI Scribe to capture "Dark Data"—the longitudinal context (GI, skin, neuro-psych) often missing from EHRs. This creates a critical pre-illness baseline for digital twins. We study the conversion of unstructured patient voice into structured, FHIR-compliant signals. | Seeking TA2 (Model-Digital Twin Generator) partners needing a robust data ingestion layer and clinician interface for mechanistic immune models. We invite TA1 (Data Acquisition) performers with ICU access to validate our "Pre-Illness Baseline" predictive models. Additionally, looking for partners with FDA regulatory expertise (SaMD) to ensure our platform meets the rigorous compliance standards of the AP2 category. | AP2: FDA-compliant Digital Twin Platform, TA1: Measure - Dynamic Immune Descriptor |
| Jonathan Gasson | CereVu Medical, Inc. | jgasson@cerevu.com | San Francisco, CA | CereVu Medical develops objective cerebral oximetry–based biomarkers for pain and dyspnea. We identify reproducible SctO₂ patterns linked to nociception, analgesic response, respiratory distress, and ventilatory load. Using multimodal physiologic data and machine learning, we model transitions to decompensation in critical illness, enabling real-time, quantitative monitoring of neurologic and immunologic stress states. | CereVu seeks clinical partners with expertise in critical care, pulmonology, anesthesiology, and immunology to support validation of objective pain and dyspnea biomarkers in acute illness. Ideal teams have access to ICU populations, experience in complex trial execution, multimodal physiologic data capture, and translational research integrating inflammatory, neurologic, and respiratory endpoints. | TA2: Model - Digital Twin Generator |
| Jessica Bishop | Ceria Therapeutics | jessica.bishop@ceriatx.com | San Juan, PR | Development of drug products in critical care to address severe, acute inflammatory conditions including sepsis, acute kidney injury, acute respiratory distress syndrome, and related conditions driven by excessive cytokine release. Ceria is seeking teaming partners for TA1 and TA2. | We are seeking TA1 and TA2 teaming partners | TA3: Modulate - Rational Immune Reprogrammer |
| David Jackson | Ceria Therapeutics, Inc. | david.jackson@ceriatx.com | San Juan, PR | Development of RNA interference drug products in critical care to address severe, acute inflammatory conditions including sepsis, acute kidney injury, acute respiratory distress syndrome, and related conditions driven by excessive cytokine release. | Ceria is seeking teaming partners for TA1 and TA2. | TA3: Modulate - Rational Immune Reprogrammer |
| Larry Bartolotti | CGI | larry.bartolotti@cgifederal.com | Fairfax, VA | CGI delivers AI- and ML-enabled digital twin platforms that integrate multimodal clinical and omics data into real-time decision support. We build secure, cloud-native, FHIR/HL7‑interoperable systems with rigorous SDLC, validation, and traceability. CGI can lead or support TA2 architecture, model integration, and clinician‑facing decision support. | CGI seeks partners with deep systems immunology and mechanistic modeling expertise to complement our digital twin platform capabilities. Ideal teammates bring immune network modeling, biomarker biology, and therapeutic domain knowledge to co-develop validated TA2 models and enhance clinical relevance. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Kim Anthony-Gonda, PhD | CGT Consulting, LLC | kagonda@cgtconsulting.us | Clarksburg, MD | My organization is a consultancy dedicated to advancing cell and gene therapies to both local and global markets. I provide strategic guidance and therapeutic development expertise to help innovators bring transformative therapies-such as CAR-T, gene editing, or RNA-based therapeutics-from development to clinical trials. | My organization is seeking partners with established (or to be established) digital twin models that can be utilized to address critical illness and dieseases, with a focus on integrating innovative 'off-the-shelf' cell and gene therapies for rapid deployment in a critical care setting. | TA3: Modulate - Rational Immune Reprogrammer |
| Ioannis Koutroulis | Children's National Hospital | ikoutrouli@childrensnational.org | Washington, DC | Sepsis, critical illness, AI-based screening tools, phenotypes, digital twins | Collaboration on technology development and data analytics | TA2: Model - Digital Twin Generator |
| Sophie Beckman | Cimit | sbeckman3@mgh.harvard.edu | Boston, MA | Cimit is a leader in health innovation with 25+ years of experience advancing groundbreaking solutions to complex health challenges. We use our hands-on approach, proven process, custom tools, and global experts to accelerate innovative ideas toward commercialization. Cimit has supported over 1500 medtech innovator teams and built specific expertise in evaluating, derisking, accelerating, and deploying novel solutions. | Cimit seeks collaborative partners that will benefit from complex project management or “integration”, engineering, product-market fit, regulatory, and commercialization support. We offer expertise in early-stage evaluation, derisking, and innovation. Partners can leverage our tailored infrastructure, tools, resources, expert network, and streamlined methodologies to address the need for early integration of commercialization and clinical translation efforts. | Other |
| Michael McCurdy | Clairyon | mike@clairyon.com | San Diego, CA | Clairyon offers multimodal AI-powered clinical intelligence solutions to deliver real-time information providers need to intervene when it matters most. Already adopted in multiple major medical centers, Clairyon's inpatient EHR-integrated platform works ceaselessly to predict adverse events, enable targeted interventions, and improve patient outcomes. Further, the Clairyon GenAI mobile health chatbot ingests and analyzes multimodal data to enable ongoing complex care outside of the hospital. | With its particular expertise in critical care, Clairyon seeks clinical sites to deploy its platform in novel manners in diverse settings. Because the platform's ability to integrate complex data from the EHR, wearables, smart devices, and direct patient communication facilitates comprehensive analyses, the Clairyon team seeks partners creating novel "smart" devices that provide further enhanced nuanced understanding of real-world clinical situations. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Kurt Hackenberger | Claryx | kurt.hackenberger@claryx.com | New York, NY | Claryx is genomic biosurveillance infrastructure for hospital environments, integrating environmental sampling with advanced molecular and sequencing methods to build a digital twin of the hospital microbiome – tracking pathogen reservoirs and antimicrobial resistance in near real time. Prospectively deployed in hospital, our platform generates continuous environmental exposure data that forms the missing upstream input layer for patient-level immune trajectory modeling. | We seek TA2 digital twin teams looking to incorporate environmental pathogen exposure data as upstream model inputs, and TA1 partners focused on host-side immune measurement to co-develop integrated measure frameworks linking environmental trigger to immune response. Clinical site partners with active ICU research programs and interest in hospital-acquired infections, sepsis, and AMR are a strong fit. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Rachel Cummings | Columbia University | rac2239@columbia.edu | New York, NY | I am an individual contributor looking to be a part of a larger team. My primary expertise is in data privacy, differential privacy, and privacy-preserving machine learning. I also have technical expertise in optimization, machine learning, algorithmic fairness, and human-computer interaction (especially how non-experts engage with novel technical tools). | I'm happy to join any team where my skills could be of value. | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Zeno Fox | Continuity | zeno@continuity.bio | Bay Area, CA | Continuous monitoring for molecular biomarkers | - | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Eamon Raith | Critical Care Research Group | e.raith@uq.edu.au | Brisbane, Queensland, Australia | CCRG is a multidisciplinary translational research group integrating clinical studies, preclinical experimentation and biomedical engineering to improve outcomes for critically ill patients. CCRG investigates mechanisms of cardiopulmonary failure including ARDS and ECMO physiology, develops novel technologies in preclinical animal models and leads large international trials and registries. A neurocritical care program examines secondary brain injury after TBI and subarachnoid haemorrhage. | CCRG seeks TA2 collaborators with expertise in systems immunology, mechanistic modelling, and digital-twin development to integrate with CCRG’s strengths in TA1 measurement, TA3 therapeutic modulation, and AP3 clinical trials platforms. Partners should develop models linking high-resolution biomarker data to immune control points and therapeutic strategies, enabling validation in ICU cohorts, preclinical platforms, and multicentre critical-care trials. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Chenkai Ma | CSIRO | chenkai.ma@csiro.au | Sydney, Australia | AI, digital twin model | Clinical partner | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform, TA3: Modulate - Rational Immune Reprogrammer |
| Chenkai Ma | CSIRO | chenkai.ma@csiro.au | Sydney, Australia | CSIRO is a multidisciplinary research organisation in Australia. We have strong research records in immunology and data science. We have already built some machine learning driven algorithms to decipher the host immune response to the pathogens, which could be translated for TA1. We are currently also working on the digital twin for ageing. | We are looking for the partners who have owned or recorded hopital datasets such ECG and SpO2 in the ICU and whom would like to utilize these data for building/training digital twin model. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Henry Tse | Cytovale Inc | henry@cytovale.com | South San Francisco, CA, CA | Cytovale's platform is a rapid low cost cellular morphological and biophysical analysis tool specifically designed for the immune system. With a commercialized sepsis diagnostic validating our approach, our technology is critical illness agnostic. We extract 100s of biophysical features per cell to create a rich dataset. Using unsupervised clustering analysis, we identify dynamic immunological groups, making us an ideal TA1 partner to track generalized critical illness trajectories in real-time. | We seek TA2/TA3 partners to leverage our high-dimensional (100+ features) TA1 cellular data mapping immune responses to critical illness. For TA2, we want to combine our unsupervised morphological dataset with other modalities into patient-specific digital twins predicting illness trajectories. For TA3, we seek clinical interventionists to map these dynamic immune states to targeted, FDA-approved immunotherapies, actively modulating control points to reduce ICU stays. | TA1: Measure - Dynamic Immune Descriptor |
| Nicholas Messina | Datavant | nickmessina@datavant.com | Kansas City, MO | Datavant is the United States' largest RealWorldData ecosystem and uses privacy enhancing technology to ensure data is usable compliantly and privately. | Datavant is interested in furthering the CIRCLE program through partnership with entities that generate digital twins, train AI models and deploy ML/AI models for critical care. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Dana Kazerooni | DementiAnalytics | dk4z@mekulu-kazerooni.com | State College, PA | Continuous, noninvasive extraction of vocal biomarkers in critically ill adults reflecting neuro‑immune dysfunction and neurocognitive impairment. High‑frequency ICU‑compatible sampling captures early divergence in immune dysregulation across etiologies and provides real‑time inputs for mechanistic digital twin modeling. | Seeking TA1 partners generating tissue‑specific immune biomarkers to pair with our continuous vocal neuro‑immune signals; ICU clinical teams for high‑frequency audio collection; TA2 modelers integrating multimodal immune data into digital twins; and TA3 groups validating intervention timing. Offering a unique, low‑burden TA1 measurement module that strengthens any integrated CIRCLE team. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Gary An | Department of Surgery, University of Vermont | gan@med.uvm.edu | Burlington, VT | We are leading a team centered around TA2 for a solution that follows the guidance from the NASEM report regarding the definition and requirements for a digital twin. Our existing virtual asset is a cellular-molecular-tissue mechanistic model of the immune dynamics following inciting perturbation(s). Our workflow includes a novel VVUQ method tailored for cellular-molecular models and integrates a variety of ML/AI methods with the explicit goal of identifying multi-modal adaptive control. | We are looking for a partner able to measure trans-dermal ISF cytokines (target ideally TNF, Il1b, IL1ra, IL10, IL8, GCSF, Il12, IFNg) and return results at 4-6 hr intervals and able to scale device production to 100s of deployable devices by Y3. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Jackie Zou | Diagnostics Research Laboratory | hongzou@gmail.com | N/A, DE | Diagnostics Research Laboratory was founded in 2019. We have been engaging with the research & procurement departments at Dx and pharma companies to access our portfolio of products including our unique cell-based tumor models and bio-samples. Currently, DRL is leveraging its biobank of 3D tumor models (organoids) from several disease nosology to build an AI-powered oncology SaaS platform that gives scientists faster, simpler sequencing analytics. | Oncology-focused research and development teams, who are interested in being early users of our platform, to provide feedback to our early-access version. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Eugene Chan | DNA Medicine | eugene@rhealth.com | Bedford, MA | We have developed a point-of-care flow cytometer that has been demonstrated in space. | We would be interested in teaming with clinical partners in academia. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Tracy Rausch | DocBox | trausch@docboxinc.com | San Antonio, TX | DocBox has created a critical care MIoT platform which normalizes and aggregiates medical device and EHR data to provide a comprehensive data set of the patient. | Looking for AI and Clinical Partners | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Andrea Webb | Draper | awebb@draper.com | Cambridge, MA | Draper is a trusted partner in Microphysiological Systems (MPS) with 20+ years of expertise in designing and building custom sensors and MPS platforms. Our capabilities have demonstrated >12 human tissue types, including disease-relevant models, and have enabled in vitro to in vivo extrapolation. Our high-throughput, human MPS platforms offer support by providing high-quality, mechanistic data generation for TA1 and drug screening capabilities for TA3. | Draper seeks to partner with a Prime team that has a comprehensive solution spanning TA1, TA2, and TA3. We bring a proven track record of collaborating with US Government, academia, and pharma partners, and expertise in human sensing, UX, and human-centered design, in addition to our MPS capabilities. We are interested in subcontracting opportunities to provide our MPS tissue models to support TA1 mechanistic data generation and TA3 drug screening. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Hao Yu | E&E BioClub | hyu@ebioclub.com | Indianapolis, IN | RNA is increasingly important in modern therapeutics. We found that over 80% of RNA transcripts produced via IVT at high magnesium levels (16 mM and 4 mM tested) were non-functional due to high mutation rates. However, most IVT protocols use even higher magnesium concentrations for yield. Our integrated process produces and packages RNA under physiological conditions, preserving integrity and enabling efficient, targeted delivery. | Organizations developing RNA-based therapeutics | TA3: Modulate - Rational Immune Reprogrammer |
| Robert Georgantas | eGlint Proteomics | Robert.Georgantas@eglintbio.com | San Diego, CA | eGlint is advancing ProteoCare™, a rapid, multiplex proteomics point-of-care platform powered by novel thermal-stability biosensors. Our focus is delivering affordable, highly sensitive, <10-minute multi-analyte testing to enable early disease detection, real-time immune monitoring, and decentralized clinical decision-making, expanding access to high-performance diagnostics in community and near-patient settings aligned with ARPA-H CIRCLE goals. | EGlint will be looking for feedback on our approach and for suitability with the CIRCLE program. While will focus on TA1, we currently have partners for TA2 and TA3 that will be part of our proposal. Yet, we would like to also explore partnering opportunities for TA2 and TA3. | TA1: Measure - Dynamic Immune Descriptor |
| John Lyons | Emory University | jdlyons@emory.edu | Atlanta, GA | My lab studies cell death pathways as drivers of inflammation and immune dysregulation during critical illness. We are interested in patterns of immune cell death in disease states and how different modes of cell death contribute to host-derived inflammatory feedback loops. We are also interested in how stress-induced alterations in gene transcription may engage innate immune receptors to trigger cell death and other inflammatory responses. | We have ready access to patient bio samples in diverse critical illness states (sepsis, trauma, ECMO, etc) and we are interested in partnering with teams with expertise in high-throughput methods like mass spectrometry and computer modeling to characterize changes in cell death and inflammatory protein markers during critical illness. | TA1: Measure - Dynamic Immune Descriptor |
| Gari Clifford | Emory University | gari@ieee.org | Atlanta, GA | Critical Care Data Platforms, AI, Biobanking, and Predictive Analytics | Partner sites and industrial collaborators with rapid testing technology | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Magha Devan | Entellimetrix LLC | mdevan@entellimetrix.com | Atlanta, GA | Entellimetrix helps public health organizations break down data silos, improve data quality, and build secure, interoperable systems that support real-time analysis. Our services strengthen situational awareness, enhance program performance, enable evidence- based decisions across all levels of public health operations and improve health outcomes. | We would like to offer Data Science/Data Analytics services to partners who are seeking companies with deep data analytics experience within the public health domain including clients like CDC, NIH, ACF, HHS, King County Community Health and others. | AP1: Critical Illness Clinical Data & Analysis Platform |
| Monika Jain | Evidation Health, Inc. | mjain@evidation.com | San Francisco, CA | Evidation enables research through a platform that has an ongoing connection to 5M individuals spanning 50 states who share multimodal (EHR, wearable, survey, biosample, other) data in exchange for rewards, health insights, and opportunities to participate in research. We have a software platform that can seamlessly engage patients from our community in research studies. | We seek partners that want to utilize our research-ready population for data collection. | Other |
| Tomas Drgon | FDA | tomas.drgon@fda.hhs.gov | Washington DC, DC | regulatory science, genAI literacy and adoption, human genetics, data science, peer review | we can provide SMEs and regulatory science consulting | AP1: Critical Illness Clinical Data & Analysis Platform |
| Kevin Tracey | Feinstein Institute | kjtracey@northwell.edu | Manhasset, NY | The body transmits sensory neural signals to the brain about its physiologic, metabolic, and immunologic status. Brain neural networks process this information and respond through reflex outputs that evolution selected to maintain homeostasis. | Expertise in neural network state configurations, processing, and behavior. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Hongyuan Cao | Florida state University | hcao@fsu.edu | Madison, WI | AI enabled prediction for vital signs with time to event outcome | Domain expert in critical care and other disease | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Yiming Huang | Foli Bio Inc. | yiming@foli.bio | New York, NY | Foli Bio develops Foli-seq, a non-invasive platform that profiles human gut mucosal transcriptome from stool via sensitive host RNA profiling. We build scalable assays and analytics to track immune/epithelial activity longitudinally, discover biomarkers, and predict clinical trajectories. We have preliminary ICU patient feasibility data showing we can capture gut host inflammatory signals relevant to critical illness and immune dysregulation. | We plan to lead TA1 (rapid, repeated immune & inflammation measurements) and seek partners to lead TA2 (mechanistic digital twin development) and TA3 (data/model-guided immune reprogramming), plus collaborators who can provide adult ICU sample access. As a biotech company, we can also lead early commercial transition planning (assay scale-up, regulatory strategy, and partner engagement). | TA1: Measure - Dynamic Immune Descriptor |
| Zoya Gluzman-Poltorak | Forta Bio | Zoya@forta.bio | Livermore, CA | Forta Bio’s ODC™ platform enables selective immune modulation and pathological cell clearance with programmable, receptor-targeted oligonucleotides. Each construct integrates conditional intracellular activation and logic-gated effector action, remaining inert unless disease-specific signals are present—supporting safer, individualized intervention. | Forta Bio seeks drug development partners with capabilities in ICU/critical illness biology, relevant in vivo models, translational pharmacology/tox, and rapid path to IND/early clinical testing for precision immune-modulating therapeutics. | TA3: Modulate - Rational Immune Reprogrammer, TA2: Model - Digital Twin Generator |
| Julia Komissarchik | Glendor, Inc | julia@glendor.com | Draper, UT | Glendor is on a mission to safeguard patient privacy while accelerating medical innovation. With its automated, at-source, at-scale PHI detection technology, Glendor enables healthcare data custodians to share and aggregate multimodal medical data —advancing clinical research, AI model training, and real-world evidence generation without compromising patients’ privacy. Glendor’s customers include government, hospitals, lab networks, pharmaceuticals, AI companies, and medical data lakes. | We provide software for automated detection and de-identification of sensitive health information across multimodal healthcare data, including medical images, scanned documents, PDFs, reports, audio, and video. The system is deployable on-premises or in cloud environments and operates entirely within partner-controlled infrastructure. We seek partners interested in applying privacy controls at the data source, including data generated internally and data contributed by external collaborators. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Johan Paulsson | Harvard Medical School | johan_paulsson@hms.harvard.edu | Boston, MA | High throughput screening of blood cells. Mathematical analyses. Diagnostics. Extraction of microbes from blood and bodily fluids. Advanced optics. Ultraparallel micro and nano-fluidics. | Digital twin work. Immunology. | TA1: Measure - Dynamic Immune Descriptor |
| Joseph Miller | Henry Ford Health | jmiller6@hfhs.org | Detroit and surround metropolitan area, MI | Clinical emergency and critical care research, integration of biomarkers in precision medicine, immunomodulation in critical illness | We have a strong clinical environment for critical care research and are looking for partners in advanced analytics and immunology | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| Pavol Genzor | Henry Jackson Foundation (HJF) | pgenzor@aceso-sepsis.org | Bethesda, MD | ACESO uses its global clinical network, multi‑omic data, computational modeling, and translational research to identify immune dysregulation in critical illness. By defining host‑response endotypes and linking them to targeted immune‑modulating therapies, ACESO accelerates discovery of disease mechanisms and development of treatments across diverse causes of critical illness. | Ideal collaborators include academic medical centers, public‑health agencies, and biopharma partners providing diverse patients, clinical data, regulatory alignment, and immuno-modulatory innovations. Added value comes from AI and modeling groups, global‑health organizations, technology companies, and patient‑advocacy groups, enabling discovery, validation, and translation of host‑directed therapies. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Alexander Charney | Icahn School of Medicine at Mount Sinai | alexander.charney@mssm.edu | New York, NY | At Mount Sinai, we conduct cutting edge research in critical care, immunology and actionable AI. We have developed a longitudinal ICU Datamart that harmonizes high resolution multimodal data for critically ill patients across the health system. Our work centers around causal inference, reinforcement learning and agent systems to estimate treatment effects, optimize intervention timing and dosing, and simulate clinical decision strategies. | We seek teaming partners with established small and large animal models of critical illness, including sepsis and multi organ dysfunction, and demonstrated expertise in immune modulation studies. Capabilities should include IACUC approved translational protocols, ICU analogous physiologic monitoring in animals and experience aligning preclinical outcomes with computational modeling. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Ankit Sakhuja | Icahn School of Medicine at Mount Sinai | ankit.sakhuja@mssm.edu | New York, NY | At Mount Sinai, we conduct cutting edge research in critical care, immunology and actionable AI. We have developed a longitudinal ICU Datamart that harmonizes high resolution multimodal data for critically ill patients across the health system. Our work centers around causal inference, reinforcement learning and agent systems to estimate treatment effects, optimize intervention timing and dosing, and simulate clinical decision strategies. | We seek teaming partners with established small and large animal models of critical illness, including sepsis and multi organ dysfunction, and demonstrated expertise in immune modulation studies. Capabilities should include IACUC approved translational protocols, ICU analogous physiologic monitoring in animals and experience aligning preclinical outcomes with computational modeling. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Abhinav Bhushan | Illinois Institute of Technology | abhushan@iit.edu | Chicago, IL | Microfluidics, sensors, and closed-loop systems | team leads | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Maksym Krutko | imec USA | max.krutko@imec-int.com | Cambridge, MA | Imec is a world leading research and innovation center in nanoelectronics and digital technologies focused on advanced semiconductor & system scaling, silicon photonics, AI, sensing, and health applications. Imec conducts interdisciplinary research at the intersection of engineering, data science, and medicine, and has extensive experience collaborating with academic medical centers, research universities, industry partners, and public funding agencies in largescale, multiinstitutional programs | imec’s research capabilities align with the program’s emphasis on quantitative, longitudinal immune characterization, model informed decision-making, and scalable translational platforms, with relevance to Technical Areas TA1 (Measure) and TA2 (Model). | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Katy Shaw-Saliba | Infinity Bio, Inc. | katy.saliba@infinitybio.com | Baltimore, MD | The immune system is a biological ledger of exposures and autoimmunity that shapes future inflammatory outcomes. Infinity Bio’s MIPSA technology decodes this ledger, the antibody reactome, via proteomic-scale DNA-barcoded libraries. Our HuSIGHT (human proteome), VirSIGHT (all viruses), and EnviroSIGHT (microbes/allergens) provide high-dimensional data at population scale. These datasets serve as the unbiased biological inputs for AI Digital Twins to predict ICU trajectories. | Infinity Bio seeks to partner with integrated teams, including computational modelers, ICU clinicians with access to biospecimens and clinical metadata, and experts in pre-clinical models, to serve as the primary engine for high-dimensional immune data collection and model training. As an industry leader in antibody reactome profiling, we provide the biological ground truth necessary to train and validate patient-specific Digital Twins. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer, AP1: Critical Illness Clinical Data & Analysis Platform |
| Imanuel Lerman | InflammaSense, UCSD | ilerman@inflammaSense.com | La Jolla, CA | InflammaSense has made significant strides in advancing its technology and securing critical support for its growth. The company has successfully navigated the regulatory landscape, obtaining a Non-Significant Risk (NSR) determination and completing key Pre-Submissions for the envisioned clinician decision support system; it focused on critical care infectious and inflammatory diagnostics using Autonomic Neurography (ANG) and miRNA technologies. These technologies are core to TA1. | We are seeking partners in TA2 and TA3. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Tim Sweeney | Inflammatix | tim@inflammatix.com | Sunnyvale, CA | Inflammatix develops rapid transcriptomic signatures for acute and critical illness, and can deploy them on our FDA-cleared Myrna(TM) device. We are an industry leader in understanding molecular subtypes of critical illness. We also have gathered likely the world's largest transcriptome database of critical illness. With academic partners, we have recently published on consensus endotypes of critical illness (Moore et al., Nature Medicine, 2025). | Inflammatix and our associated teaming partners are looking for additional clinical study sites, groups experienced in building digital twins, and groups deploying sophisticated algorithms into the EHR. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Luca Emili | InSilicoTrials | luca.emili@insilicotrials.com | Wilmington, DE | We provide a commercial deployed cloud platform (US and worldwide) enabling partners to develop, integrate, and productize computational models, and digital twin for in silico trials, including critical illness and immunomodulation. Leveraging our own scientific capabilities, we also develop models across multiple theraputic areas, making them accessible to non-expert user through multi-model workflow orchestration supporting FDA compliance submission. We perform in the ARPA-H Catalyst program | InSilicoTrials seeks teaming partners with expertise in: clinical management of critically ill patients (ICU, trauma, burn, sepsis); mechanistic computational modeling of immune-inflammatory pathophysiology; biomarker data acquisition, and multi-omics; and adaptive clinical trial design. We welcome partners who can co-develop digital twin models to be hosted and productized on our platform, enabling seamless integration into FDA compliant in silico trials workflows for the CIRCLE program. | AP2: FDA-compliant Digital Twin Platform, TA2: Model - Digital Twin Generator |
| Naeha Subramanian | Institute for Systems Biology | nsubrama@systemsbiology.org | Seattle, WA | The Subramanian laboratory at the Institute for Systems Biology studies innate immune regulation and host–pathogen interactions using systems immunology approaches. Current work integrates longitudinal multi-omic profiling, computational analysis, and experimental immunology to identify dynamic immune signatures that govern inflammatory responses and disease trajectories in infectious and inflammatory disorders. | We seek collaborators with access to critical care clinical cohorts and expertise in translational immunology to link longitudinal, high-resolution immune measurements with clinically meaningful disease trajectories. We also welcome partnerships with groups specializing in computational modeling and digital twin development, as well as teams developing immune modulation strategies or clinical trial infrastructure to test predicted immune control points. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Stefano Finazzi | Istituto di Ricerche Farmacologiche Mario Negri IRCCS | stefano.finazzi@marionegri.it | Milan, Italy | The Laboratory of Clinical Data Science coordinates the GiViTI network, which is partner of the International ICU network LOGIC. For GiViTI we manage a registry of over 200 ICUs and an EHR-based data collection system used in 80 ICUs in Italy. Its mission is to assess and improve quality of care and conduct clinical research in the field of critical care medicine. Activities include regulatory management, software development for data collection, and statistical and machine-learning analyses. | We seek partners to complement our expertise, including immunology groups with accredited labs for advanced immunophenotyping and multi‑omics assays; teams skilled in developing advanced digital‑twin systems integrating mechanistic and machine‑learning models for real‑time immune‑response modeling; and international ICU collaborators to complement our existing clinical sites for multicenter studies. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Ayse Gurses | JHU | agurses1@jhmi.edu | Baltimore, MD | The Center for Human Factors in Healthcare at Johns Hopkins Armstrong Institute conducts research on clinical work systems, cognitive work, and the safe integration of AI in healthcare. Our work combines field studies, cognitive task analysis, and systems engineering to understand real-world diagnostic and critical care work and inform the design and evaluation of AI-enabled tools and digital twin technologies that support clinician sensemaking, coordination, and resilience. | Ideal collaborators include clinical researchers and technology developers interested in translating models into FDA-compliant platforms and designing tools that integrate into real-world ICU workflows and support clinician decision-making. | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform |
| Jadumani Singh | JR Analytics | jaduromi@jranalytics.com | Adelaide, South Australia, Australia | JR Analytics focuses on digital health innovation at the intersection of critical care and data science. Our work involves developing clinical software platforms and data-driven models to support decision-making in acute care settings. Current projects include AI-assisted interpretation of viscoelastic coagulation testing (ROTEM), predictive modelling using ICU and emergency datasets, and digital tools for clinical documentation and workflow improvement. | JR Analytics seeks partnerships with organisations developing digital twin models, training AI systems, and deploying machine learning solutions for critical care. We are particularly interested in collaborators working on computational modelling of physiological and immune responses, integration of ICU clinical data, and translational applications that support real-time decision-making in critically ill patients. | AP1: Critical Illness Clinical Data & Analysis Platform, Other |
| Cameron Gardner | KAIJU Bio | cameron@kaiju.bio | San Francisco, CA | KAIJU Bio develops programmable targeting ligands (“duramers”), entropy-constrained circular DNA aptamers that direct therapeutic payloads to specific cell types in vivo. Duramers enable precise targeting of immune and tissue cells by binding diverse surface proteins including GPCRs and ion channels and can be coupled to delivery platforms such as LNPs, viral particles, and protein nanoparticles to enable cell-specific nucleic acid or protein delivery. | We seek partners with clinically relevant delivery systems for nucleic acid or protein therapeutics (e.g., LNPs, viral vectors, or nanoparticle platforms). Ideal collaborators are developing immune-modulating payloads such as CAR systems, genome editors, or transcriptional regulators. KAIJU contributes programmable targeting ligands to enable precise in vivo delivery to defined immune cell populations. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Kate Burdekin | Kayvea LLC | kate@kayvea.com | Durham, NC | Kayvea LLC is a research data strategy and informatics consulting firm specializing in data governance, AI-ready data infrastructure, and multi-site clinical research coordination support for federally funded programs. Our work spans NIH coordinating center operations, FAIR data architecture, OMOP and NIH Common Data Element harmonization, privacy-preserving data platform implementation, synthetic data initiatives and interoperability strategy for complex, heterogeneous clinical datasets. | Clinical SME in Critical Care / ICU Digital Twins — a physician-scientist with hands-on experience in critical illness patient data, mechanistic immune modeling, or ICU digital twin development. This advisor will guide data product design, validate synthetic data fidelity for digital twin training, and serve as a liaison to TA performer teams. | AP1: Critical Illness Clinical Data & Analysis Platform |
| Rachel Clipp | Kitware | rachel.clipp@kitware.com | Carrboro, NC | Kitware is a research and development company with a history of developing and maintaining open source solutions, including the digital twin platform, Pulse Physiology Engine. Our team of medical computing experts has significant experience with multi-scale, multi-physics models of the human response to disease, trauma, and treatment. Our open-source computaional physiology engine can be leveraged to create a digital twin of the immune response during critical illness. | We are looking to join a TA2 or AP2 team to create a digital twin of the immune response. We are looking for a team that include high-fidelity models of the immune response and ICU clinical partners that can supply medical expertise and data for model development and validation. | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform |
| Christopher Stricklan | Kraetonics, LLC. | chris@kraetonics.com | West Melbourne, FL | Working on the ARPA-H UPGRADE program to help hospitals respond to cyber threats. Developing AI models to facility an understanding for the hospital stakeholders on the threats, remediations, and clinical workflow assesment. | Looking for TA1 and TA3 partners. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Renee Winzar | La Trobe University | r.winzar@latrobe.edu.au | Melbourne, Australia | Australian Centre for AI in Medical Innovation (ACAMI) is an AI research centre based at La Trobe University, Melbourne with a focus on applying AI and machine learning techniques to advance medical research. ACAMI’s Prof. Nilmini Wickramasinghe has publications developing digital twin models for heart failure, diabetes, dementia, cancer, pediatric care and clinical decision-making, with a specific focus on sensor enabled data collection and practical integration into clinical workflows. | ACAMI is eager to join a team of passionate clinicians looking to make a real-world impact by proving the utility of digital twins in clinical practice. Prof. Nilmini Wickramasinghe has worked with the Cleveland Clinic, so is familiar with US hospital systems and practices, and frequently travels to the US for ongoing collaborations with US academic institutes. We also have expertise in federated learning models, a flexible approach to training AI without the need to offshore patient data. | TA2: Model - Digital Twin Generator |
| Dina Weilhammer | Lawrence Livermore National Laboratory | weilhammer1@llnl.gov | Livermore, CA | Our team focuses on multi-omic immune profiling to define host responses to infection and disease. We integrate animal models and human-relevant microphysiological systems with bulk and single-cell transcriptomics, spatial transcriptomics, cytokine measurements, and metabolomics to characterize immune cell states, signaling networks, and tissue microenvironments. This systems-level approach reveals mechanisms of pathogenesis and informs therapeutic strategies. | We seek collaborators with access to well-annotated clinical data in critical illness and established connections with the FDA to support regulatory alignment. Partners advancing translation-ready technologies that can move efficiently from discovery to clinical application are especially valued. | TA1: Measure - Dynamic Immune Descriptor |
| Nicholas Be | Lawrence Livermore National Laboratory | be1@llnl.gov | Livermore, CA | We apply AI/ML for longitudinal clinical data, including medical foundation models that learn patient trajectories from labs, vitals, and EHR signals. We advance trajectory modeling and digital twin methods via predictive modeling, uncertainty quantification, and simulation in areas including inflammatory states, acute trauma, and infection. LLNL maintains world-class high performance computing resources to enable model training and large-scale simulation efforts relevant to this program. | We are seeking partners with clinical and FDA compliance expertise in critical illness to guide phenotype definitions, as well as strong instrumentation and assay capabilities to measure immune and inflammatory parameters at clinically relevant cadence. Partners with the ability to support prospective clinical sample and data collection for model development and validation are especially valuable. | AP1: Critical Illness Clinical Data & Analysis Platform, AP2: FDA-compliant Digital Twin Platform |
| Hollis O'Neal, Jr. | LSUHSC - New Orleans (Baton Rouge Campus) | honeal@lsuhsc.edu | Baton Rouge, LA | I am an Associate Professor of Medicine in Pulmonary & Critical Care, and I have a research interest in the host responsive. Over the last 12 years, I have worked in collaboration with Cytovale, Inc, a Biotechnology company in San Francisco to develop a novel host diagnostic for sepsis. We have continued to develop this technology though assessing the functional changes in the immune system that we see in physical stress (ie strenuous exercise) and other immune-mediated diseases. | As we continue to develop our understanding of immune-mediated disease and the role that the dysfunctional host response plays in many conditions (sepsis, trauma, inflammatory bowel disease, rheumatologic disease), we hope to gain a better understanding of the host response, including how to better assess it as well as explore options in manipulating this response to aid in the treatment of this family of diseases and pathologic conditions. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Zachary Plotkin | Lumos Health PBC | zach@projectlumos.org | New York, NY | Lumos Health is building a Large Physiological Model (LPM)—a physics engine for the human body. Unlike reductionist LLMs, our engine uses the Manifold Hypothesis to compress 125Hz waveforms into a latent space, modeling continuous-time dynamics. We have achieved a 0.975 AUROC for mortality, predicting vascular collapse 6.5 hours before clinical alerts. Leveraging Mamba-2 and explainable Neurosymbolic layers, we provide real-time ICU "Stability Forecasts". | We seek clinical partners and Academic Medical Centers to expand our Federated Network. We provide our software as Research-Use Only to partners in exchange for local model training on diverse, real-world patient data (vitals, labs, outcomes) without data leaving the firewall. Specifically, we are looking for ICU/Critical Care departments and safety pharmacology leads interested in validating in-silico cardiotoxicity and hemodynamic forecasting. | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform, AP1: Critical Illness Clinical Data & Analysis Platform, TA1: Measure - Dynamic Immune Descriptor |
| Zachary Plotkin | Lumos Health PBC | zach@projectlumos.org | New York, NY | Lumos Health is building a Large Physiological Model (LPM)—a physics engine for the human body. Unlike reductionist LLMs, our engine uses the Manifold Hypothesis to compress 125Hz waveforms into a latent space, modeling continuous-time dynamics. We have achieved a 0.975 AUROC for mortality, predicting vascular collapse 6.5 hours before clinical alerts. Leveraging Mamba-2 and explainable Neurosymbolic layers, we provide real-time ICU "Stability Forecasts". | We seek clinical partners and Academic Medical Centers to expand our Federated Network. We provide our software as Research-Use Only to partners in exchange for local model training on diverse, real-world patient data (vitals, labs, outcomes) without data leaving the firewall. Specifically, we are looking for ICU/Critical Care departments and safety pharmacology leads interested in validating in-silico cardiotoxicity and hemodynamic forecasting. | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform |
| Diego Rey | Maiten | diego@rey.bio | San Francisco, CA, CA | Endotype identification and therapeutic development. | Reducing mortality and morbidity in sepsis and ARDS. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer, AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| James Lederer | Mass General Brigham and Harvard Medical School | jlederer@bwh.harvard.edu | Boston, MA | Our research program addresses how traumatic injuries alter the immune system. Beyond our basic immunology program, we also develop therapeutic interventions that work by reprogramming the immune system and restore immune homeostasis. We use systems immunology approaches like CyTOF and flow cytometry, transcriptomics, and proteomics to provide comprehensive insights into dynamic cellular and systemic changes that occur following injury and infection in patients and preclinical models. | We are interested in organizing a team that would complement our data-driven approach to trauma and critical illness immunology. Groups with system biology computational expertise and machine learning methods would provide perfect partners. We have access to patient samples and preclinical models to generate immune profiling data for computational modeling. Our therapeutic interventions for trauma use trained immunity pathways for immune reprogramming to improve immune function and recovery. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Eric Rosenthal | Massachusetts General Hospital | erosenthal@mgh.harvard.edu | Boston, MA | Our organization develops infrastructure and methods for trustworthy, mechanistically grounded AI in critical care. We integrate large-scale real-world ICU data with prospective physiology-focused trials to enable actionable clinical insights. This includes the NIH Bridge2AI CHoRUS program harmonizing 112K ICU admissions with waveforms, imaging, EHR medications, flowsheets, and notes, and participation in real-time physiology trials through the SIREN and SCCM Discovery networks. | With an established platform for data acquisition, hosting, and standardization for AP1 and expertise for AP2 in ICU physiology modeling, we are interested in a potential computational immunology partner to ensure our AP2 approach is comprehensive and immunologically focused. | AP1: Critical Illness Clinical Data & Analysis Platform, AP2: FDA-compliant Digital Twin Platform |
| Joel Voldman | Massachusetts Institute of Technology | voldman@mit.edu | Cambridge, MA | We have expertise in sample-sparing molecular and cellular measurement of the immune system, along with clinical collaborators in critical illness. On the measurement side, we have been developing small-volume (microliter) assays to measure molecules and cell function, in minutes, from patients (both central line and fingerstick). We are part of a team using these methods in ARDS and sepsis. | We are seeking expertise on digital twin modeling. | TA1: Measure - Dynamic Immune Descriptor |
| Matt Maciejewski | MatGen LLC | matt@matgenlabs.com | Cambridge, MA | MatGen builds hybrid mechanistic + ML digital twins of biological and chemical systems, integrating physics-based models, omics data, and experimental outputs into iterative design platforms. We implement lab-in-the-loop workflows where models propose experiments, data updates the twin, and cycles optimize molecules, materials, or processes under multi-objective constraints. | Experience in quick experimental iteration and developing high-volume measurements that can be then modeled. | TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Nicholas Semenkovich | Medical College of Wisconsin | nsemenkovich@mcw.edu | Milwaukee, WI | At the Medical College of Wisconsin (MCW), our ICUs maintain a strong research focus with consistently high clinical trial enrollment. Our research programs are led by Dr. Semenkovich, Dr. Jay Patel, and Dr. Rodney Willoughby. We study micronutrients, gasotransmitters, and other interventions that may alter disease trajectory in septic shock. We are also developing deep-learning approaches with an emphasis on liquid biopsy technologies (cfDNA and cfRNA). | We are seeking key partners for development of digital twins from our expansive clinical data, and can serve as a clinical site for analytical approaches that advance the goals of this CIRCLE mechanism. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform, TA3: Modulate - Rational Immune Reprogrammer |
| Raj Ratwani | MedStar Health | raj.m.ratwani@medstar.net | Columbia, MD | MedStar Health consists of 9 acute care hospitals across the greater Maryland and Washington DC area of the United States. The case mix index for our system in 2025 was 3.62 with an average ICU length of stay of 3.39 days. Across the ICUs in our 9 hospitals, there were a total average daily census of 335 patients in the ICU with a total of 19,880 admissions in 2025. All patients are cared for by a dedicated critical care team overseen by trained intensivist. | We can collect and build databases of high frequency real time physiologic data (i.e. vital signs, hemodynamics, ventilator parameters, pressure-transduced waveforms), collect diagnostic data including laboratory samples, microbiologic samples, along with medical imaging, and administer pharmacologic and device protocols in the ICU. We are looking to partner (as a sub) and any of the TAs or APs. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform, TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Seife Yohannes | MedStar Health Research Institute | seife.yohannes@medstar.net | Washington, DC, DC | MedStar Health Research Institute is involved in several immunological and clinical trials. | Looking for a basic science research expert and lab. We will provide the clinical platform and trial patients. | AP3: Critical Illness Clinical Trials Platform, AP3: Critical Illness Clinical Trials Platform |
| Anand Muthusamy | Melody FRO | anand@convergentresearch.org | Los Angeles, CA | As a focused research organization, we coordinate and execute R&D projects in continuous molecular monitoring and design closed-loop interventions. We engineer new biosensors and sampling schemes to address different compartments with ~minute resolutions. We develop mechanistic, interpretable physiological models that incorporate immune and cardiometabolic biomarkers and are aware of drug titration (closed loop). We share tools openly and develop commercial pathways for sustainability. | Research teams with expertise in relevant animal models; biotech companies with specialty in rapid drug delivery systems or nerve stimulation; clinical teams who treat critically ill adult patients across diverse etiologies and have run adaptive trials. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Eran Eden | MeMed | amir.nakar@me-med.com | Haifa, Israel | MeMed develops FDA-cleared rapid host-response diagnostics enabling near–real-time immune profiling. Our MeMed Key© platform measures multiple proteins from whole blood in 15 minutes. MeMed BV, our first test, integrates 3 proteins using machine learning to distinguish bacterial and viral infection. We bring end-to-end expertise in proteomics, bioinformatics, clinical validation (>20,000 patients), assay & software development, V&V, manufacturing, and regulatory experience with FDA. | We seek to join a clinically driven CIRCLE team led by a strong integrator. We are looking for partners with deep ICU expertise and experience conducting prospective studies in critically ill populations. We will contribute proteomics, bioinformatics (including advanced models), rapid assay development, software and systems engineering, and regulatory expertise to support TA1, partnering through clinical validation, regulatory strategy, and deployment to achieve real-world impact. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Jennifer Buell | MiNK Therapeutics | jennifer.buell@minktherapeutics.com | New York, NY | MiNK Therapeutics is a clinical-stage immunotherapy company developing deployable immune cell platforms for acute inflammatory and trauma-associated conditions, including polytrauma. Our lead asset, agenT-797, is an off-the-shelf allogeneic invariant Natural Killer T (iNKT) cell therapy that has been evaluated across five clinical trials in cancer and severe inflammatory indications, providing a human safety and translational dataset directly relevant to critical illness immuno-inflammation. | We seek collaborators with complementary strengths in Measure (TA1) and Model (TA2) to build an integrated, end-to-end CIRCLE team capable of not only repurposing FDA-approved therapies, but also seamlessly implementing MiNK’s TA3 modulation platform clinically. | TA3: Modulate - Rational Immune Reprogrammer |
| Michelle Gong | Montefiore Medical Center | MGong@Montefiore.org | Bronx, NY | Prediction and prevention of acute organ failure and critical illness and its complications. Our research is focused on the fact that critical illness can occur anywhere in the hospital from the emergency department to hospital floor to the intensive care unit. Our research harnesses the electronic health record to create an acute learning health system to facilitate observational studies and clinical trials focused on improving outcomes and recovery in patients with acute critical illnesses. | Multicenter large cohorts of hospital wide critical illness for developing embedded precision approaches to the prevention and treatment of acute critical illness and emergencies | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| Joseph Bogan | MRIGlobal | jbogan@mriglobal.org | Kansas CIty, MO | MRIGlobal is a non-profit 501(c)(3) organization and recognized leader in Global Health since 1944. MRIGlobal operates core biological laboratories including 1,500 ft² of CAP-accredited clinical labs. Since 2019, we have developed 70+ clinical assays, resulting in 26 EUA, 15 510(k), and 5 de novo FDA clearances. Our Regulatory Affairs team provides end-to-end support for IVD development, including FDA engagement, V&V studies, and clinical validation under GCP and ISO standards. | MRIGlobal will leverage its Microphysiological System (MPS) platform to enable personalization and modeling of systemic infection and injury. The MPS will include integrated fluidic circuits, including lung, spleen, lymphoid, and BBB/hippocampus modules. High resolution biomarker mapping across these modules will provide the mechanistic, time resolved data needed for the Digital Twin to learn immune dynamics and deliver individualized predictions and therapeutic guidance. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Jim StClair | MyLigo, Inc | jim.stclair@myligo.io | Austin, TX | Digital Twin Integration "glue": provide zero trust agent/architecture, work package decomposition, interface specs, and a credible integration and test plan, AI Agent integration. Data assimilation and measurement: pipelines, data quality metrics, provenance, and governance for instrumented platforms and multi source fusion. | Clinical engagement, diagnostic technology, data analysis, clinical subject matter experts | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform |
| June Lee, MD, PhD | National Society of Medical Scientists (NSMS) | Dr.JuneLee@nsmsusa.org | Bethesda, MD | National Society of Medical Scientists (NSMS) develops clinical intelligence architectures for real-time control of immune dysregulation in critical illness. Our H6 team of intensivists, emergency physicians, clinical pharmacologists, and AI healthcare architects specializes in the closed-loop “measure–model–modulate” paradigm integrating immune sensing, digital twin modeling, and automated therapeutic modulation. The program builds on 11 patented innovations supporting CIRCLE TA1–TA3. | NSMS seeks partners in high-frequency immune sensing (multi-omics, biosensors), mechanistic digital twin modeling, scalable AI/HPC infrastructure, and ICU clinical trial networks. Ideal collaborators include academic medical centers, biotechnology innovators, and AI technology groups advancing TA1 sensing, TA2 predictive modeling, and TA3 therapeutic modulation for closed-loop immune control. | TA3: Modulate - Rational Immune Reprogrammer, TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| June Lee, MD, PhD | National Society of Medical Scientists (NSMS) | Dr.JuneLee@nsmsusa.org | Bethesda, MD | NSMS (est. 1996) provides elite clinical leadership in "Clinical Intelligence for Agentic AI". Our team of intensivists, emergency physicians, and clinical pharmacologists specializes in the "measure-model-modulate" loop for critical illness. We focus on identifying mechanistic "control points"—molecular/cellular triggers—and optimizing the timing and spatial precision of repurposed FDA-approved therapies to prevent Multi-Organ Dysfunction Syndrome (MODS). | NSMS seeks partners specializing in TA1 (high-frequency microfluidic/omic sensing) and TA2 (mechanistic computational modeling) to form an integrated "Team Integrator" proposal. We provide the clinical oversight and pharmacology expertise required for TA3 interventions and AP3 clinical trial execution. We aim to partner with teams capable of achieving the <15-minute data-to-intervention latency required for rational immune reprogramming. | TA3: Modulate - Rational Immune Reprogrammer, TA2: Model - Digital Twin Generator |
| Mohammed Eslami | Netrias, LLC | meslami@netrias.com | North Bethesda, MD | Our organization offers AI-driven aggregation of heterogeneous clinical and biological datasets to support multi-institutional research. We provide large curated data products along with including AI-based query tools, to accelerate modeling and analysis. By ensuring FAIR principles and HIPAA-compliant de-identification, we guarantee a secure, interoperable database and tools that meets strict standards for ICU-integrated clinical care. | We are looking for partners capable of hosting a multi-institutional, high-security environment. Domain and standard experts would also be welcomed. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| James Dieffenderfer | NIRSense | James@nirsense.com | Morrisville, NC | Our primary focus is on novel biophotonic sensing modalities (heart rate variability, tissue oxygen saturation, core temperature) that can be integrated into a variety of different wearable formfactors (watch, adhered patch, etc) | We are looking to support a clinical or data analyst prime through novel sensing of relevant biomarkers. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Gilles Clermont | NOMA AI, Inc. | g.clermont@noma.ai | Pittsburgh, PA | We do multimodal machine learning leveraging EHR and high-resolution physiology signals, in real-time. We are developing xAI tools to promote end-user trust. We also focus on system implementation, reliability and usability, emphasizing clinical decision support within existing clinical workflows. We are also familiar with neural ODE and existing efforts at mechanistic simulations of the inflammatory response. We are also familiar with the FDA clearance process. | Although we can leverage very large datasets, we believe that additional point-of-care bioassays (e.g. sepsis on a chip or POC immunograms) will greatly enhance biomarker driven therapy, as well as monitoring response to therapy. Current approaches ML approaches to optimize therapies are likely fundamentally flawed and would greatly benefit from solid mechanistic underpinnings. Partners with extensive experience in adaptive RCT design of sepsis would be invaluable. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Roger Narayan | North Carolina State University | roger_narayan@ncsu.edu | Raleigh, NC | Our research centers on advanced biomedical materials and device development. Key focus areas include optical and electrochemical biosensors for point-of-care diagnostics, microneedle platforms for transdermal biosensing, and laser-based advanced manufacturing techniques including 3D printing. We investigate infection biomarker detection. Our work bridges biomedical engineering, materials science, electrochemistry, and clinical translation. | We welcome partners in the commercialization of point-of-care diagnostic devices and the clinical validation of electrochemical biosensors. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Roger Narayan | North Carolina State University | roger_narayan@ncsu.edu | Raleigh, NC | Our research group specializes in biosensor development and diagnostics for critical illness, with particular emphasis on microneedle-based minimally invasive platforms capable of real-time biomarker monitoring. We are integrating machine learning and AI-enhanced signal processing to improve diagnostic specificity and enable patient stratification. | TA2 expertise in mechanistic, multiscale computational modeling and digital twin development for immune/inflammatory systems; TA3 expertise in immunomodulatory therapeutics; clinical ICU access; regulatory and commercialization experience | AP1: Critical Illness Clinical Data & Analysis Platform, TA1: Measure - Dynamic Immune Descriptor |
| Ashkan Afshin | Novelna Inc. | ashkan@novelna.com | Palo Alto, CA | Novelna is a biotech startup specializing in AI-enabled deep proteomics for biomarker discovery and liquid biopsy diagnostics. | Seeking partners with: (1) ICU clinical sites with access to diverse critically ill patient populations (trauma, sepsis, post-surgical, chronic disease exacerbation) and established IRB infrastructure for prospective biomarker sample collection; (2) Immunology/immunomodulation researchers experienced in repurposing FDA-approved therapies for immune dysregulation in critical illness, with pre-clinical validation capabilities (TA3). | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Donghoon Lee | Omphalos Lifesciences Inc | donghoon.lee@omphaloslifesci.com | Dallas, TX | Omphalos excels in system-level, fully kinetic digital twin development, cross-TA integration, and mechanistic control point discovery. We build biologically grounded, data-trained hybrid models that integrate multiscale, spatiotemporal, multimodal data to simulate immune dynamics and therapeutic modulation. Our scalable framework has been tested in viral and bacterial systems and dyslipidemia human disease models. | We seek strong TA1 and TA3 partners to complement our modeling leadership. For TA1, we prioritize ICU teams capable of high-frequency, multiplexed, tissue-attributed immune biomarker acquisition and longitudinal sampling in adult pulmonary ICU patients. For TA3, we seek collaborators with adaptive trial execution and FDA-facing experience in immunomodulatory and digital health interventions. | TA2: Model - Digital Twin Generator |
| Huw Davies | Owlstone Medical | huw.davies@owlstone.co.uk | Cambridge, United Kingdom | Owlstone Medical has a number of programs ongoing to develop breath‑based biomarkers and point of care detection methods that could be used to monitor host immune activity and pathogen burden. These biomarkers reflect inflammation, oxidative stress, and pathogen‑specific signatures (e.g. pseudomonas) with the potential to integrate into diagnostic and monitoring workflows with ventilator‑compatible sampling and pathways towards real‑time detection for implementation in critical care settings. | We seek partners with ICU patient access, suitable cell culture model systems, and expertise in critical illness or infectious disease. Ideal collaborators include clinical teams working with relevant patient populations and groups developing or deploying immunologic or antimicrobial interventions that could benefit from Owlstone’s breath‑based biomarker insights, point of care analysis technologies and computational modelling, for integration into ICU decision‑making workflows. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Elizabeth Crone | Owlstone Medical Ltd | elizabeth.crone@owlstone.co.uk | Cambridge UK | Owlstone Medical has a number of programs ongoing to develop breath‑based biomarkers and point of care detection methods that could be used to monitor host immune activity and pathogen burden. These biomarkers reflect inflammation, oxidative stress, and pathogen‑specific signatures (e.g. pseudomonas) with the potential to integrate into diagnostic and monitoring workflows with ventilator‑compatible sampling and pathways to real‑time detection for implementation in critical care settings. | We seek partners with ICU patient access, suitable cell culture model systems, and expertise in critical illness or infectious disease. Ideal collaborators include clinical teams working with relevant patient populations and groups developing or deploying immunologic or antimicrobial interventions that could benefit from Owlstone’s breath‑based biomarker insights, point of care analysis technologies and computational modelling, for integration into ICU decision‑making workflows. | TA1: Measure - Dynamic Immune Descriptor |
| Ewan Hunter | Oxford Biodynamics lc | ewan.hunter@oxfordbiodynamics.com | Oxford, England, UK | Oxford BioDynamics is a biotechnology leader focused on 3D genomics. Its proprietary EpiSwitch® platform identifies the spatial folding patterns of DNA to create highly accurate, clinically actionable biomarkers for precision medicine. EpiSwitch maps the genome’s functional architecture rather than just its code. OBD transforms genomic data into predictive intelligence.This enables healthcare providers to bridge the gap between genetic risk and functional reality, improving patient outcomes. | We would be interested in groups who wish to develop more informed knowledge environments by filling in the gaps to biomedical knowledge by looking at the 3D genome. These can be solutions developers, equally working with clinicians who have well annotated NGS data to generate knowledge maps to augment the data space we have currently developed. We have extensive data on autoimmunity and immunity in oncology | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Rauf Izmailov | Peraton Labs | rizmailov@peratonlabs.com | Basking Ridge, NJ | AI/ML research & development. | Medical expertise. | TA2: Model - Digital Twin Generator |
| Debkishore Mitra | Pheresys, Inc. | debkishore.mitra@gmail.com | Palo Alto, CA | Pheresys, Inc. is developing a first-in-class extracorporeal blood processing system designed to selectively remove Pathologically Deformable Immune Cells (PDIC) with aberrant mechanical and structural properties. PDICs have been linked to immune dysregulation and organ failure, most recently in sepsis patients. Our team includes the inventor of deformability cytometry (Prof. DiCarlo) an physicians specializing in critical care medicine. We are interested in leading a TA team as Team Integrator. | We are seeking teaming partners with expertise in TA1 and TA2. For TA1, we are specifically looking for technical competency or research interest in measuring and quantifying biophysical biomarkers such as deformability, density etc. For TA2, we are looking for research interest in using computational models to stratify organ failure risk based on a variety of biomarkers. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Debkishore Mitra | Pheresys, Inc. | debkishore.mitra@gmail.com | Palo Alto, CA | Pheresys Inc. is developing a first-in-class extracorporeal blood-processing system designed to selectively remove Pathologically Deformable Immune Cells (PDIC) with aberrant mechanical and structural properties. PDICs have been linked to immune dysregulation and organ failure, most recently in sepsis patients. Our team includes the inventor of deformability cytometry (Prof. DiCarlo) and physicians specializing in critical care medicine. We are interested in leading a TA team as Team Integrator. | We are seeking teaming partners with expertise in TA1 and TA2. For TA1, we are specifically looking for technical competency or research interest in measuring and quantifying biophysical biomarkers such as deformability, density etc. For TA2, we are looking for research interest in using computational models to stratify organ failure risk based on a variety of biomarkers. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Andrew Omidvar | Philips | andrew.omidvar@philips.com | Washington, DC | We are one of the global leading organization for critical care solutions, platform, Patient monitoring. | Innovative solution with path to commercial market. | AP1: Critical Illness Clinical Data & Analysis Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| Nicusor Iftimia | PHYSICAL SCIENCES INC. | nicusor.iftimia@gmail.com | Andover, MA, MA | TA1 - Non-Invasive Wearables for Inflammation Monitoring; TA2- Dev of digital twin models | Clinical partners | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| John Jedziniak | PhysioSense | john@physiosense.ai | Centennial, CO | PhysioSense develops physiological signal analytics and digital phenotype models from noninvasive biosignals, including PPG and related waveform data. Our work focuses on interpretable modeling of vascular, autonomic, and systemic physiology; time-series feature extraction; disease-state and trajectory inference; multimodal data fusion; and software tools that support critical illness monitoring, digital twin development, and clinical data analysis. | We are seeking partners with strengths in critical care clinical datasets, immunology, host-response modeling, digital twin platforms, FDA-regulated software, and clinical validation. We are especially interested in teams with access to ICU/clinical trial data, assay or biomarker expertise, translational medicine experience, and platform partners who can integrate physiological analytics into broader decision-support systems. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Thomas Berti | Planned System International | Tberti@plan-sys.com | Arlington, VA | PSI is a full-spectrum IT, clinical systems and engineering services company with 35+ years of federal healthcare experience. PSI is a proven ARPA-H performer having won two ARPA-H programs - one as a prime and the other as a partner. PSI capabilities span cloud-native EHR deployments, cybersecurity, IT modernization, medical modeling, digital twins & simulation clinical services and AI/Date platforms. PSI is open to providing expert prime cabilbilites as we'll co-prime or sub roles. | PSI is seeking partners with expertise in systems immunology, biomarkers measurements (TA1) | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform, AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Carlos Lopez-Espina | Prenosis | carlos.lopez-espina@prenosis.com | Chicago, IL | Prenosis is a biology-based tech company improving outcomes in time-critical, high-mortality conditions by tailoring care to each patient’s biology. Using the NOSIS biobank and deep proteomics, the Immunix EHR-integrated platform, and AI-biomarkers (diagnostic, prognostic, predictive), we deploy workflow-integrated decision tools at scale, and precisely match patients to therapeutics to de-risk development, accelerate precision clinical trials, and advance novel biomarker-guided therapies. | Prenosis seeks partners that accelerate precision medicine in acute care: (1) therapeutic partners with immunomodulator assets that can be matched to biology using our NOSIS-driven AI biomarkers; (2) academic collaborators to advance discovery and validation on the NOSIS dataset; and (3) nstrument and assay developers who want to extend the clinical reach of their protein-measurement platforms by integrating them with Prenosis AI-biomarkers into an end-to-end solution for critical illness. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Richard Andrews | ProThera Biologics | rickandrews575@gmail.com | Providence, RI | ProThera is developing the blood protein Inter Alpha Inhibitor (IAIP) to ID and treat patients at risk of sepsis. IAIP is an immune modulator essential in controlling systemic inflammatory responses during infection, trauma & stroke. Our published data from patient samples confirm declining blood levels of IAIP correlate highly with progression and that replacement therapy improves survival and organ damage in models of sepsis and stroke. We have a rapid POC test and IAIP therapy in development | ProThera technology adds a new critical element to the comprehensive strategy needed to ID and treat patients at risk for sepsis. The Company seeks teams that can build DT models incorporating our biological systems approach and using our access to critical care patient cohorts. ProThera provides TA-1 Measure dynamic immune Descriptor and TA-3 Modulatory, Immune Reprogramming that when integrated with computational strategies can significantly improve patient outcomes. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Yow-Pin Lim | ProThera Biologics | yplim@protherabiologics.com | Providence, RI | ProThera has identified an actionable host response biomarker based on innate immunity proteins, that are rapidly depleted during systemic inflammation. The rapid quantification serves as a predictive tool to inform and guide the replacement protein therapy in restoring the immune response homeostasis that has demonstrated beneficial effects in reducing mortality in preclinical models. The combined strategy of Rapid Test & Replacement Therapy allows an effective personalized critical care. | ProThera is seeking to join with a team that can build an integrated DT model using our unique biological systems approach and access to critical care patient s where we can make a significant difference in critical care. ProThera will provide both TA-1 & TA-3 and when integrated with a computational strategy, will dramatically improve patient outcomes. We would welcome the opportunity to share our findings and ideas with your Team. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Christina Ramires Ferreira | Purdue University | cferrei@purdue.edu | West Lafayette, IN | I am expert in high throughput and spatial metabolomics and lipidomics analyses and in method development. We are currently able to acquire untargeted lipidomics and metabolomics data in two seconds using a HT DESI system which resulted from DARPA Make It program (PI: Graham Cooks). This technology can support rapid and comprehensive data to support biological digital twin efforts. The platform can also be use do quantify small molecules and for HT enzymatic bioassays. | Partners who need high throughput and/or spatial metabolomics and lipidomics data | TA1: Measure - Dynamic Immune Descriptor |
| Jasmine LaCoursiere | QLHC | j.lacoursiere@qlhc.org | San Francisco, CA | Quantum Leap Healthcare Collaborative (QLHC) designs and operates adaptive platform clinical trials in critical illness and oncology. Our iSpy trials are an established model for complex, biomarker-driven platform trials at scale. The iSpy site network is proven in rapidly collecting meaningful biological data and translating findings to the bedside. | QLHC seeks partners with expertise in computational modeling or digital twin development for critical illness. We bring clinical trial infrastructure and real-world data assets, and are looking to close the loop — connecting model-derived hypotheses directly to adaptive trial execution. | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| Paul Henderson | Quantum Leap Healthcare Collaborative | p.henderson@quantumleaphealth.org | San Francisco, CA | Platform clin ical trials in ARDS and Breast Cancer | CIRCLE Teams that can leverage our I-SPY-ARDS platform trial capabilities | AP3: Critical Illness Clinical Trials Platform, AP2: FDA-compliant Digital Twin Platform |
| Juliane Sempionatto | Rice University | jsemp@rice.edu | Houston, TX | testing and development of wearable biosensors and point of care sensors | partners for data analysis | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Juliane Sempionatto | Rice University | jsemp@rice.edu | houston, TX | I am an assistant Prof at Rice University working with wearable and point of care biosensors for tracking immune system, including IL-6, IL-8, TNFa biosensors for ISF, saliva and sweat | We are seeking collaborators to integrate our wearable device as a user interface for the early-detection algorithm. By combining continuous molecular biomarker tracking with machine-learning inference, the wearable can provide actionable early alerts. In addition, biosensor-derived physiological signatures can be leveraged to personalize the model and improve performance over time. | TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| Juliane Sempionatto | Rice University | jsemp@rice.edu | Houston, TX | I am an assistant professor from Rice University, working on wearable biosensors and point of care devices. I am currently developing a biosensor (for ISF, sweat or saliva) for the detection of IL-6, IL-8, and TNFa for tracking the immune system. | I am looking for a team to integrate my sensors and generate data for the AI/machine learning application. My wearable sensors can be the end user interface of the algorithm that can predict outcomes at early stage based on real time data and machine learning | TA1: Measure - Dynamic Immune Descriptor, AP3: Critical Illness Clinical Trials Platform |
| Ioannis Androulakis | Rutgers University | yannis@soe.rutgers.edu | New Brunswick, NJ | Our long-term goal is to enable a trustworthy, deployment-ready ICU decision support that anticipates impeding deterioration early enough to support precision intervention, while explicitly communicating uncertainty, data quality and evidence. The overall objective is to develop and validate agentic ICU digital twins in which modality-specialist predictive agents generate multi-horizon forecast of patient health trajectories and imminent adverse events. | We are looking for additional clinical partners for deployment and testing as well as developer experts. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Solveig Sieberts | Sage Bionetworks | solly.sieberts@sagebase.org | Seattle, WA | Sage Bionetworks is a non-profit research organization with a mission to enable and accelerate biomedical research through data sharing, collaboration, model evaluation and ethical data governance. Notably, our data sharing platform hosts PBs of data, largely focusing on -omics data. We host a number of NIH data sharing portals, numerous model benchmarking efforts and are awardees under the ARPA-H BDF program to develop data curation tools. | While we have extensive experience with -omics data, we are looking for partners with strong experience in the processing and harmonization of clinical data. We would also be interested in partners with subject matter expertise and/or experience with FDA filing, and potentially partners with analytical tools to augment our own. | AP1: Critical Illness Clinical Data & Analysis Platform, AP2: FDA-compliant Digital Twin Platform |
| Garrett Hoard | Schism Labs | garrett@schismlabs.com | San Francisco, CA | Accurate Neuron Simulation for Non-Local Bio-Physical field interactions | Microtubule Researchers looking for safe experimental and classified environments. | TA3: Modulate - Rational Immune Reprogrammer, AP2: FDA-compliant Digital Twin Platform |
| Bo Lora | Scientix.ai Inc | bolora@scientix.ai | 106 6th St Suite 900-152 Austin TX 78701, TX | We build provenance-native knowledge infrastructure for healthcare and life sciences. Our Provenance Neural Engine creates a temporally-aware, ontology-grounded knowledge graphs using open standards (NGSI-LD/JSON-LD, FHIR, CDISC, SNOMED, LOINC, MedDRA, etc.) We specialize in connecting fragmented clinical data across systems & organizations with full temporal provenance, governed AI execution with audit trails, federated data sharing, & LLM-powered analytical tools on validated portable infra. | Seeking clinical research teams with ICU/Critical illness expertise, access to patient cohort data, and biomarker measurement capabilities. Ideal partners include academic medical centers with active critical illness research programs, computational immunologists building digital twin models, & organizations with existing critical illness datasets. We provide the data infrastructure, provenance layer, AI execution & AI governance. Partners provide the clinical domain expertise & data generation. | AP1: Critical Illness Clinical Data & Analysis Platform, AP2: FDA-compliant Digital Twin Platform |
| ddot dan | SELFdXb | ddotdan@selfdxb.com | Los Angeles, CA | 2008-2018 successfully proved to counter aging, degenerative issues and avoided spine fusion surgery for human subject. Leading us to solving systems biology questions. To inducing systemic systems biology by expediting microcirculation without active exercise toward whole person health. From blood plasma ecm thru Fascial Communication Network Infrastructure beyond connective tissue. 2/19/2026 | Specialist in systems biology, immune, lymphatic, internal respiratory, mitochondrial systems. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Vivek Sharma | Senescope | vivek@senescope.com | San Ramon, CA | Senescope develops AI models detecting cellular senescence from routine blood smears and tissue images. Validated in Nature Aging and Lancet Digital Health with 6,000+ patients, our scores correlate with cytokines IL-6/IL-8. This enables rapid immune state assessment in minutes from standard samples. We offer the potential for serial monitoring to track inflammatory trajectories and provide high-fidelity data for ICU digital twins | We seek partners in three areas: (1) researchers with access to ICU cohorts and biobanked samples for validation; (2) computational immunologists building predictive immune models; and (3) teams developing digital twins who need rapid immune data. We provide senescence assessment in minutes from routine blood smears, enabling serial monitoring to track inflammatory trajectories and guide immunotherapy decisions. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Young-Jae Cho | Seoul National University Bundang Hospital | lungdrcho@snu.ac.kr | Seongnam, Gyeonggi-do, South Korea | We are working clinically and translationally to improve outcomes for critically ill patients in the ICU. 16 ICU beds in the medical ICU and 18 in the surgical ICU are currently used for severe respiratory and cardiac diseases. We have translational labs for NAMs, such as organoids (from human-derived tissues or iPSCs) and organ-on-a-chip (e.g., EmulateBio), for complex in vitro models of the lungs or heart. We also had various experiences with critically ill animal models, including MV & ECMO. | All teams seeking clinical data on critically ill patients in the ICU, esp. in non-US Asian areas. It's a good fit for our team, especially for those with TA2 & AP2. | TA3: Modulate - Rational Immune Reprogrammer, AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| Young-Jae Cho | Seoul National University Bundang Hospital | lungdrcho@snu.ac.kr | Seongnam (Postal code 13620, South Korea) | We are working clinically and translationally for the critically ill patients in the ICU. 16 ICU beds for medical ICU and 18 beds for surgical ICU are currently used for the severe respiratory and cardiac diseases. We also have a tranlational labs for NAMs, such as organoids and organ-on-a-chips. | All of other teams who are seeking the clinical data of critically ill patients in the ICU, esp. in the non-US, Asian area | AP1: Critical Illness Clinical Data & Analysis Platform, TA3: Modulate - Rational Immune Reprogrammer |
| Lenny Moise | SeromYx Systems | lenny.moise@seromyx.com | Woburn, MA | SeromYx combines a broad repertoire of high throughput antibody effector function assays and machine learning to enable rapid, scalable, high-throughput, and high-resolution profiling of immune signatures of disease progression, protection, and resolution. Our platform delivers actionable biological insights at clinical and population scale and has been applied across infectious disease, inflammation, cancer, and neurodegeneration, supporting the full discovery and drug development continuum. | SeromYx seeks teaming partners in the following areas: critical illness treatment and care, AI/ML modeling, real-time patient monitoring, adoption of assays for clinical use, precision immunology, and immune reprogramming interventions. We are open to roles as: Technical lead or Subcontractor (assay development and analytics) in TA1. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Steve Xu | Sibel Health Inc. | stevexumd@gmail.com | Chicago, IL | We developed advanced, flexible wearable sensors across the entire continuum of care. We have 8 FDA clearances and enable monitoring across the entire care spectrum. Our wearable sensors offer multiplexed capability for continuous multilead ECG, PPG, acoustomechanic, motion, and temperature sensing. | We would be happy to provide sensors and technologies for capturing critical care physiological data with raw data download. | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Gene Godbold | Signature Science, LLC | ggodbold@signaturescience.com | Charlottesville, VA | RNA seq analysis to find and identify biomarkers. Active in two working groups in the Gene Ontology Consortium: (1) Immunology and (2) Multiorganism Interactions; We’ve developed new GO terms for innate immune exploitation by microbes, including inflammatory pathways. We're also good at proposal development (red/gold teaming). | (1) Project lead integration (2) Clinical expertise in critical illness treatment with access to abundant patient data (3) Expertise in modeling relevant physiological systems (4) Expertise in digital twin generation for MODS/inflammation/innate immunology (5) Clinical expertise with immunomodulatory therapy for what are likely to be relevant inflammatory and immunosuppressive pathways necessary for successful interventions | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Jacob Heggestad | SimplusDx | j.heggestad@simplusdx.com | Durham, NC | SimplusDx offers a rapid, multiplex point-of-care diagnostic platform for quantitative biomarker measurement. The system combines low-cost disposable cassettes with an inexpensive portable detector to measure 6 - 10 biomarkers (e.g., cytokines, chemokines, other inflammatory biomarkers) from a small volume (< 50 uL) of undiluted whole blood in < 30 minutes. This performance is enabled by a non-fouling polymer brush surface that suppresses biological noise and enables highly sensitive detection. | We seek TA2/TA3 partners to leverage our POC platform, which can be deployed for use in critical care and high-acuity settings to guide treatment and patient monitoring. | TA1: Measure - Dynamic Immune Descriptor |
| Yoon Seong Jeon | Sotirion Biosciences | yoon.jeon@sotirion.com | 20271 Goldenrod Ln, Germantown,, MD | Sotirion biosciences is a AI powered disease diagnostic company using human’s adaptive immune system. Existing diagnostic technologies depend on the physiological changes which can be detected long after disease development in human body. Sotirion technologies can detect disease earlier than conventional methods even before physiological change occurs using human immune response. Its initial focus is hematologic cancers detection and will expand to neuro diseases such as Autism and Alzheimer. | We are looking for (pre) clinical collaborators who can potentially work with us to prove the clinical validity of our technologies. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Constantinos Panousis | Sotirion Biosciences | constantinos.panousis@sotirion.com | Germantown, MD | Sotirion Biosciences is a startup company that has developed a seven chain immune repertoire assay (SIRA) and an AI Immune Digital Health Platform (AIIMD) to diagnose multiple conditions efficiently in one streamlined platform, for Cancer, Autoimmune and Neurological Diseases. | We are looking for Clinical Partners. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Lloyd Mitchell | Splice Therapeutics | lgm@splice.one | Germantown, MD | We invented and develop spliceosome mediated RNA trans-splicing. It's in a clinical trial, replacing 22 exons of ABCA4 (>3,300 nt) delivered by a single AAV. No other gene editor can match it. | We are looking for pre-clinical and clinical partners | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Tina Hernandez-Boussard | Stanford University | boussard@stanford.edu | Palo Alto, CA | Our group, led by Drs Hernandez-Boussard and Gevaert, has expertise across three areas: (1) developing digital twin models to understand and control complex disease trajectories; (2) integrating multimodal clinical data (e.g., EHR, biomarkers, and physiological signals) to model complex disease dynamics such as critical illness; and (3) translating real-time predictions into therapeutic control points, in silico digital trials, and clinical decision support evaluated in prospective studies. | We seek partners with complementary expertise in rapid immune biomarker sensing, critical care medicine, and therapeutic modulation of immune pathways. Ideal collaborators include ICU physician scientists and clinical trial networks capable of rapid patient enrollment, teams with high-frequency immune profiling capabilities, and groups developing immune-modulating therapies that can be integrated with digital twin models to guide real-time interventions. | TA2: Model - Digital Twin Generator, AP2: FDA-compliant Digital Twin Platform, AP3: Critical Illness Clinical Trials Platform |
| Andrew Moore | Stanford University | armoore7@stanford.edu | Stanford, CA | Our group, led by Drs. Angela Rogers and Purvesh Khatri, has extensive expertise across three key components: (1) interrogation of immune heterogeneity to make sense of the underlying biology in critical illness (as evidenced by the Hi-DEF immune framework (Nat Med PMID 41028543, 2025); (2) translation of these findings to point-of-care immune assays (as evidenced by the TriVerity device developed with collaborator Tim Sweeney and Inflammatix); and (3) precision ICU clinical trial design. | Our group is searching for key partners to: (1) aid in development and deployment of electronic health record surrogates for immune dysfunction across systems, and (2) participate in rapid enrollment to validate EHR and immune assays and evaluate therapeutic response in a Phase II immune reprogramming trial. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Angela Rogers | Stanford University | ajrogers@stanford.edu | Stanford, CA, CA | Our group, led by Drs. Angela Rogers and Purvesh Khatri, has extensive expertise across three key components: (1) interrogation of immune heterogeneity to make sense of the underlying biology in critical illness (as evidenced by the Hi-DEF immune framework (Nat Med PMID 41028543, 2025); (2) translation of these findings to point-of-care immune assays (as evidenced by the TriVerity device developed with collaborator Tim Sweeney and Inflammatix); and (3) Precision ICU clinical trial design | Our group is searching for key partners with expertise in : (1) development and deployment of electronic health record surrogates (mirrors) for immune dysfunction in critical illness, and (2) rapid enrollment in ICU populations to validate EHR and immune assays and evaluate therapeutic response in a Phase II immune reprogramming trial | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Purvesh Khatri | Stanford university | pkhatri@stanford.edu | San francisco, CA | Our group, led by Drs. Angela Rogers and Purvesh Khatri, has extensive expertise across three key components: (1) interrogation of immune heterogeneity to make sense of the underlying biology in critical illness (as evidenced by the Hi-DEF immune framework (Nat Med PMID 41028543, 2025); (2) translation of these findings to point-of-care immune assays (as evidenced by the TriVerity device developed with collaborator Tim Sweeney and Inflammatix); and (3) precision ICU clinical trial design | Our group is searching for key partners to: (1) aid in development and deployment of electronic health record surrogates for immune dysfunction across systems, and (2) participate in rapid enrollment to validate EHR and immune assays and evaluate therapeutic response in a Phase II immune reprogramming trial | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Marc Melcher | Stanford University | melcherm@stanford.edu | Palo Alto, CA | The Stanford Surgical ICU and Abdominal Transplant Divisions would like to leverage CyTOF and RNA-seq to characterize complex immune signatures to inform post-operative management in the Surgical ICU and subsequently on the floor. Our primary focus is developing AI-facilitated decision-making tools that synthesize multi-omic data and clinical variables, providing predictive analytics to optimize organ longevity and personalize transplant medicine. | We are looking for technology partners with expertise in high-frequency lab assessment and digital twin modeling. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Pamela Abshire | Stony Brook University | pamela.abshire@stonybrook.edu | Stony Brook, NY | We are developing miniaturized high throughput sensors that can be used to track immune and autoimmune responses at point of care. The devices leverage highly manufacturable CMOS technology. | We are looking for clinical partners. Our team is located in Stony Brook, NY, and College Park, MD. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Nathan Collins | Synfini Inc. | nathan.collins@synfini.com | Menlo Park, CA | Working with a partner we are developing a near–real-time epitranscriptomic monitoring platform. Using nanopore sequencing, the system will continuously read RNA and its chemical modifications from small blood samples to quantify immune activation, suppression, and stress responses. Rapid analysis will convert RNA modification patterns into a dynamic immune-state signature, enabling early detection of immune dysregulation and guiding timely intervention in critically ill patients. | We seek a teaming partner with deep expertise in critical care medicine and clinical research to support access to ICU patient populations, longitudinal biospecimen collection, and clinical data integration. Ideal partners have experience in immune monitoring, translational studies, and clinical trial execution, enabling validation of near-real-time epitranscriptomic immune state monitoring in critically ill patients. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Gita Parekh | Tachmed | gita.parekh@tachmed.com | London UK, and Phoenix, Arizona | Our organization develops electrochemical biosensor technologies for rapid, multiplex detection of clinically relevant biomarkers at the point of care. Our research focuses on translating sensitive laboratory assays into portable sensing platforms capable of monitoring dynamic biological processes and disease trajectories. The goal is to enable real-time biomarker measurement to support clinical decision-making and data-driven patient monitoring. | We seek partners with expertise in critical care, immunology, systems biology, computational modelling, and clinical validation. Collaborators with access to clinical cohorts, biomarker discovery capabilities, or AI-driven disease modelling are of particular interest. Partnerships that support clinical evaluation, data integration, and translation of biomarker monitoring technologies into healthcare settings would be ideal. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Caroline DeBerry | Tenagrity Solutions | caroline@tenagrity-solutions.com | Fairfax, VA | Hospital-in-one vital sign monitoring RPM (one has already been developed and is / will soon be in use by Mayo) | We are in urgent need of funding. | AP1: Critical Illness Clinical Data & Analysis Platform, AP2: FDA-compliant Digital Twin Platform |
| Evan Maltz | Tessel Biosciences | evan@tessel.bio | Cambridge, MA | We discover drugs for immune and inflammatory diseases like COPD that are frequently precursors to critical illness. To enable this work, we build high-throughput, organotypic models of lung, gut, kidney, and BBB. Using our tissue-level phenotypic data, we build digital twins of human organs for target discovery and causal modeling of disease. We are also building foundation models for generative small molecule design against novel targets. We are a current ARPA-H CATALYST performer. | We are looking for TA3 and TA1 partners with ICU patient access, longitudinal biomarker data, and systems immunology expertise. Our mechanistic AI framework makes interpretable, patient-specific predictions from sparse data, directly applicable to digital twin development for immune dysregulation. Our in-house wet lab capabilities enable us to iterate quickly and continuously validate our models throughout the R&D process. We are flexible in terms of leading or supporting a consortium. | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Elaheh Rahbar | Texas A&M University | erahbar@tamu.edu | College Station, TX | We run an advanced computational cardiovascular lab for trauma, hemorrhagic shock & critical care. Our lab has extensive experience with acquiring real-time hemodynamic and biomarker data from various animal models of shock/injury and develop novel computational methods to evaluate time-dependent changes in inflammation, thrombosis and endothelial function. Our lab has experience with computational FE modeling, statistics, machine learning and artificial intelligence based models. | We'd love to partner with groups who have more clinical data (from humans). | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Ya Wang | Texas A&M University | ya.wang@tamu.edu | college station, TX | Contextualized Personalized Learning to allow for authentic, skill-based assessmen; Nanomedicine for therapeutics. | I am looking for a partner with critical illness clinical data | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Jim Song | Texas A&M University Health Science Center | jus35@tamu.edu | College Station, TX | Our organization focuses on immunometabolism, T-cell engineering, and microbial-based immunotherapies to modulate immune responses in cancer and autoimmune diseases. We develop engineered bacterial platforms, cellular therapies, and immune-modulatory strategies designed to remodel disease microenvironments, overcome treatment resistance, and accelerate translation from preclinical innovation to clinical application. | We seek teaming partners with complementary expertise in translational immunology, synthetic biology, advanced bioengineering, GMP manufacturing, regulatory strategy, and clinical trial execution. Ideal collaborators bring scalable platform technologies, robust computational/AI capabilities, or validated disease models that accelerate bench-to-IND development and enable high-impact, milestone-driven innovation. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Bashir Morshed | Texas Tech University | bmorshed@ttu.edu | Lubbock, TX | Additive inkjet printing (IJP) fabrication of flexible biocompatible electronics, wearables/IoT, with resource constrained low-power real-time Neuro-Symbolic AI for monitoring, detection, prediction, and health status. | Potential collaborators in this area, especially medical and clinical expertise. | AP1: Critical Illness Clinical Data & Analysis Platform, TA2: Model - Digital Twin Generator |
| Craig Ramirez | Tezcat Biosciences | craig@tezcat.co | New York, NY | Tezcat Bio specializes in the discovery and development of innate immune cell-targeted protein-drug conjugates to deliver potent immunomodulators. For the ARPA-H CIRCLES program, Tezcat proposes utilizing its innate immune cell-targeted TLR7/8 antagonist to reprogram the hyper-inflammatory innate immune response in critical illnesses (e.g. sepsis, cytokine storm, ARDS), providing a control point to shift the immune system from a path of collateral tissue damage toward resolution and repair. | Tezcat is seeking partners for TA1 and TA2 to complete a multi-disciplinary team. | TA3: Modulate - Rational Immune Reprogrammer |
| Bryan Smith | The Ohio State University | smit2901@msu.edu | Columbus, OH | We develop myeloid/monocyte-targeted nanomedicines to reprogram innate immune responses in critical illness (e.g., sepsis, ARDS). Our platforms enable selective immunomodulation with reduced off-target effects and translational scalability. We also build imaging-enabled nanocomposites that quantify in vivo drug release and tissue exposure, enabling dose–response mapping for integration with computational immune-control systems for closed-loop immune control (TA3). | We seek partners developing immune state sensing, ‘twin’ predictive modeling, and adaptive control platforms for critical illness (TA1/TA2). Our goal is to integrate targeted myeloid nanotherapies, supported by quantitative drug-release imaging, with real-time immune monitoring to enable closed-loop control of dysregulated inflammation in critical conditions such as sepsis and ARDS. | TA3: Modulate - Rational Immune Reprogrammer, AP3: Critical Illness Clinical Trials Platform |
| Parijat Bhatnagar | Tribe Research | xparijat@gmail.com | San Francisco, CA | Cell therapies and biomanufacturing | Our interest is in providing immune-engineering support to the prime. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Vrad Levering | Triple Ring Technologies | vlevering@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic partners. We have engaged with ARPA-H as sub and multiparty. We offer capabilities in device and system integration, project management, biomarker detection instruments, software dev, assay dev, sample prep automation, and complex fluid management. ISO 13485 cert. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and design, as well as complex system integration. We can contribute to TA1, and act as Team Integrator if appropriate. We are looking for teaming partners that could use our collaborative assistance. We have acted as primary, subcontractor, multiparty team, or vendor on previous submissions. | TA1: Measure - Dynamic Immune Descriptor, Other |
| Kasie Bailey | Truveta | kasieb@truveta.com | Bellevue, WA | Truveta provides nationally representative, daily refreshed longitudinal EHR RWD spanning over 135 million patients across inpatient, outpatient, ER and critical care settings. For immune modeling and critical illness research the data set includes ICU relevant elements such as vital signs, lab values, medication adminstration records, procedure and device data, ventilatory support indicators, and ADT timestamps. This enables training, validating, and operationalizing modeling. | Teams who need real time RWD that represents every state and census region representing 1 in 3 Americans. Truveta has daily refreshed data received from 30 health systems (900 hospitals and 20,000 clinics). Truveta data has structured and unstructured data available. | TA2: Model - Digital Twin Generator, Other |
| Sameer Sonkusale | Tufts University | sameer.sonkusale@tufts.edu | Medford, MA | Sonkusale Research Labs at Tufts University has pioneered several biosensing sample-to-answer diagnostic platforms for the monitoring of inflammatory cytokines and metabolic biomarker. Our platforms can work with blood, serum, interstitial fluid or saliva. Please check out https://scholar.google.com/citations?user=Bm8PgGkAAAAJ&hl=en for related publications. Our team has also pioneered drug delivery platform that can provide dose and time controlled drug delivery transdermally. | Clinical Partners, Digital Twin Generators, Immune Targeted Therapies | TA1: Measure - Dynamic Immune Descriptor |
| Zhangsheng Yang | U.S. Army Institute of Surgical Research | zhangsheng.yang.ctr@health.mil | Fort Sam Houston, TX | Developing novel therapeutic interventions for the prevention and treatment of combat-related wounds | Therapeutic drugs that prevent trauma-induced organ failure. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Paul Vespa | UCLA | pvespa@mednet.ucla.edu | Los Angeles, CA | Neuroimmune biomarker discovery in traumatic brain injury and neurocritical illness | Seeking to define immune targets for reprogramming interventions in traumatic brain injury and neurocritical illness | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Jennifer Wilson | UCLA | jenniferwilson@g.ucla.edu | Los Angeles, CA | We simulate drug off targets effects and then compare simulations to the University of California Health data warehouse (an EHR with > 10 million patients). Relevant to this proposal, we can identify matched patients based on several traditional covariates as well as simulated effects for active prescriptions and create large "digital twin" cohorts that can identify patterns and predict ICU admissions. | We would be eager to combine our computational work with any molecular characterization of immune cell function or diagnostics that would give us greater precision in predicting ICU admissions. | TA2: Model - Digital Twin Generator |
| Aydin Babakhani | UCLA | aydinbabakhani@ucla.edu | Los Angeles, CA | Wearable and biosensors | We build a wearable for monitoring immune systems. We look forward collaborate with other proposing teams. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Richard Leuchter | UCLA (David Geffen School of Medicine) | rleuchter@mednet.ucla.edu | Los Angeles, CA | Our expertise is on multimodal data collection and banking of innovative data streams. We have built a robust framework for collecting acute phase markers on all hospitalized patients, including those critically ill, and organizing these data for the purposes of AI model training. We have experience developing AI architectures from these data, and implementing models in rigorous RCTs. In addition to addressing TA1, we are positioned to react to models' outputs by delivering precision therapy. | Additional expertise in model development that can address TA2 | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Edilberto Amorim | UCSF | amorim@ucsf.edu | San Francisco, CA | The Amorim Lab at UCSF integrates neurocritical care, multimodal brain monitoring, and advanced analytics to improve recovery after acute brain injury. Led by Dr. Edilberto Amorim, the lab transforms continuous EEG, imaging, physiologic, EHR, and biomarker data into interpretable machine-learning tools for ICU decision support. For the ARPA-H CIRCLE initiative, it links systemic inflammation and immune dysfunction to brain network injury to guide targeted interventions. | We seek partners in immunology, systems biology, and biomarker development; teams advancing rapid bedside diagnostics or biosensors; experts in multimodal AI, causal modeling, and real-time ICU decision support; and collaborators in adaptive clinical trials of immunomodulatory or neuroprotective therapies. Regulatory and implementation expertise for scalable deployment is highly valued. | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Jonathan (Jack) Reid | Unicorn Biotechnologies | jack.reid@unicornb.io | Newark, NJ | Unicorn Bio designs, builds, and ships autonomous instruments for life science and clinical applications. Core capabilities: precision fluidics, closed-loop process control, multi-sensor integration, embedded and cloud software (21 CFR Part 11), and regulatory-grade hardware (ISO, MDF for FDA submission). We operate cell & molecular biology, electromechanical, and software development, and rapid prototyping/manufacturing under one roof. Founded by scientists to help scientists. | We are looking for teams that need a hardware and software engineering partner to design, manufacture, and deploy autonomous instruments for clinical or laboratory use. We take sensing or analytical modalities developed by others and wrap them in deployable, regulatory-grade instrumentation with integrated data infrastructure. 3-phase programs with a clinical endpoint and a clear path to FDA/CE clearance are ideal. | TA1: Measure - Dynamic Immune Descriptor |
| Patrick Walker | Uniformed Services University | patrick.walker@usuhs.edu | Bethesda, MD | High fidelity preclinical models of critical illness and systemic inflammatory/immune response to injury | Expertise in high fidelity in silico models of inflammatory/immune responses to traumatic and pathogenic insults | TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Ciprian Ionita | University at Buffalo | cnionita@buffalo.edu | Buffalo, NY, NY | Our group integrates clinical data science and computational modeling for neurovascular disease. We maintain a curated patient database capturing baseline, intraoperative, and postoperative trajectories. We develop physics-informed neural networks constrained by angiographic imaging to estimate vascular hemodynamics. We also implement federated learning pipelines on Google Cloud and deploy scalable AI agents and Kubernetes-based infrastructure through UB startup collaborations. | We seek collaborators with complementary expertise in large-scale clinical datasets, advanced imaging, device development, and clinical translation. Ideal partners include groups with access to diverse patient populations, digital health platforms, or novel sensing technologies that can integrate with our hemodynamic modeling, federated learning infrastructure, and AI deployment pipelines to enable multi-site validation and real-world implementation. | TA2: Model - Digital Twin Generator, TA1: Measure - Dynamic Immune Descriptor |
| Derek Russell | University of Alabama at Birmingham | dwrussell@uabmc.edu | Birmingham, AL | precision trial platform in ARDS | An ideal partner will be facile with high dimensional data and biological systems pathway modelling for estimation of causal contributors to critical illness outcomes | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| peter morris | University of Alabama at Birmingham | pmorris@uabmc.edu | Birmingham, AL | Adult and pediatric critical care from Emergency Department to hospital discharge and into out-patient clinic, home follow up. We specialize in the effectiveness of frailty assessments, work-life space assessments and rendering continuity of care from critical illness through out patient follow up | Partnering with groups to define end points of critical illness investigational work that have short and longer term patient value | AP1: Critical Illness Clinical Data & Analysis Platform, Other |
| Abu Mosa | University of Alabama at Birmingham | asmosa@uabmc.edu | Birmingham, AL | Aligned to AP1, our research focuses on creating a secure, shared critical-illness clinical data and analytics platform: governed EHR cohort/dataset generation via UAB Medicine’s DataLENS honest-broker model; informatics methods and reusable pipelines through DBIDS; scalable CPU/GPU analytics on the Cheaha supercomputer; and HIPAA-eligible hybrid cloud AI on Azure and Google Cloud under BAAs. | Seeking CIRCLE AP3 partners for AI-driven target trial emulation: health systems with ICU EHR/omics and outcomes data; causal inference/TTE methodologists; ML/MLOps teams for scalable, explainable models; and clinical trial/intervention groups to prospectively validate findings and support translation/commercialization. | AP1: Critical Illness Clinical Data & Analysis Platform, AP3: Critical Illness Clinical Trials Platform |
| James Ford | University of California San Diego | jaf020@health.ucsd.edu | San Diego, CA | Sepsis phenotyping, machine learning based sepsis diagnostic assistance, precision sepsis therapeutic modeling | Partners can help with TA3: Testing of immunomodulatory interventions in the context of critical illness | TA1: Measure - Dynamic Immune Descriptor, TA1: Measure - Dynamic Immune Descriptor |
| Mark Ansel | University of California San Francisco | mark.ansel@ucsf.edu | San Francisco, CA | Computational and cellular, molecular, and spatial analyses of human immune-mediated diseases | Innovators in uniting analysis of clinical and EHR data with detailed immunophenotyping | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Ksenia Zlobina | University of California Santa Cruz | kzlobina@ucsc.edu | Santa Cruz, CA | Complex large scale data analysis, including time-series transcriptomics, proteomic biomarker search for predicting critical health states, computational biology, mathematical modeling, dynamical systems in biology, critical states. | Clinical collaborator that investigates specific illness of critical health state, interested in early prediction of health risks, with availability to critical patient cohorts. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Yosuke Tanigawa | University of California, Los Angeles | tanigawa@ucla.edu | Los Angeles, CA | The UCLA Tanigawa Lab investigates the interindividual differences in disease. To model disease heterogeneity, we develop statistical models and computational tools for biologically grounded digital twins using genetic, multi-omic, and clinical data. We have built robust genetic prediction models across 800+ human traits. Our goal is to develop interpretable AI/ML tools to nominate the most effective disease intervention strategy and advance precision medicine. | We seek collaborators in critical care medicine, immunology, and critical care to validate the digital twin system for their real-time immune phenotyping in critically ill patients. We are looking for partners with expertise in longitudinal profiling, immunomodulatory interventions, and clinical trial design. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Aaron Meyer | University of California, Los Angeles | ameyer@ucla.edu | Los Angeles, CA | Our research group specializes in computational systems immunology, utilizing tensor factorization to uncover interpretable patterns in high-dimensional molecular data. We focus on integrating longitudinal omics and other molecular measurements to link immunological signatures with patient outcomes. By employing neural ODEs, we model patient trajectories and simulate counterfactuals, creating a mathematical foundation for "digital twins" that predict disease progression. | Interested in groups with novel, rich data sources and who would benefit from modeling to help precisely select and time interventions. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Marcella Gomez | University of California, Santa Cruz | mgomez26@ucsc.edu | Santa Cruz, CA | Data-driven modeling of complex biological systems and control algorithms that enable real-time sense and response strategies for autonomous intervention. | We are a purely computational lab. We are looking to partner with an experimentalist. We are also interested in working with folks with high-dimensional mechanistic models to couple our ML methods with. We have experience mapping complex dynamics to linear representations on small-dimensional latent spaces with temporally sparse, noisy, and small datasets. Pairing ML with mechanistic models can be powerful. We care about dynamics. | TA2: Model - Digital Twin Generator, AP1: Critical Illness Clinical Data & Analysis Platform |
| Aaron Esser-Kahn | University of Chicago | apekay@gmail.com | Chicago, IL | ML-guided immunomodulator selection and (10,000+ compounds, 55 datapoints/compound across NF-κB/IRF pathways). Real-time cytokine biosensing via issue-interfaced hydrogel transistors and microfluidics. ICU clinical access via sepsis biorepository and APS Consortium. Large-scale biomedical data commons (2.9PB) and population-scale disease modeling (151M patient records). Integrated bench-to-bedside team: engineering, AI, critical care. | Multi-site ICU clinical trial networks with sepsis patient enrollment. FDA regulatory expertise for digital twin validation (AP2). Commercial diagnostics partners for point-of-care cytokine sensing. Computational physiological modeling teams bridging cellular to organ-system scales. Pharma/biotech with GMP manufacturing for immunomodulator candidates. Medicinal chemistry and PK/PD modeling for lead optimization. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| Aaron Esser-Kahn | University of Chicago | apekay@gmail.com | Chicago, IL | ML-guided immunomodulator discovery (10,000+ compounds, 55 datapoints/compound across NF-κB/IRF pathways). Real-time cytokine biosensing via stretchable bioelectronics and microfluidics. Trained immunity reprogramming without acute inflammation. ICU clinical access via sepsis biorepository and APS Consortium. Large-scale biomedical data commons (2.9PB) and population-scale disease modeling (151M patient records). Integrated bench-to-bedside team: engineering, AI, critical care. | Multi-site ICU clinical trial networks with sepsis patient enrollment. FDA regulatory expertise for digital twin validation (AP2). Commercial diagnostics partners for point-of-care cytokine sensing. Computational physiological modeling teams bridging cellular to organ-system scales. Pharma/biotech with GMP manufacturing for immunomodulator candidates. Medicinal chemistry and PK/PD modeling for lead optimization. | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Aashish Priye | University of Cincinnati | aashish.priye@ucmail.uc.edu | Cincinnati, OH | We develop microfluidic and 3D-printed sample-to-answer diagnostic devices: rapid nucleic-acid amplification, biosensor assays, and low-cost point-of-care platforms. Capabilities include photothermal heating, assay integration, and flow/transport modeling to enable robust, fieldable biomarker monitoring. | Seeking partners with critical-care clinical access and longitudinal patient samples; immunology/host-response biomarker expertise; data + modeling teams building patient-specific digital twins; and industry/regulatory partners for cartridge manufacturing, analytical/clinical validation, and deployment studies. | TA1: Measure - Dynamic Immune Descriptor |
| John Repine | University of Colorado School of Medicine | john.repine@cuanschutz.edu | Aurora, CO | We are developing a high-resolution measure to identify immune status in real time using a unique rat model that innately resists acute lung inflammation, oxidative stress, and injury. | Organizations that can translate and test this approach for use in human critical care diagnosis and treatment guidance and assessment. | TA1: Measure - Dynamic Immune Descriptor |
| Philip Efron | University of Florida | philip.efron@surgery.ufl.edu | Gainesville, FL | Predicting and endotyping patients who will enter chronic critical illness prior to the onset of disease as well as using precision medicine to determine immuno-inflammation therapeutics. We actively obtain transcriptomic, epigenomic, proteomic, and metabolomic data (both leukocyte and non-leukocyte) on patients (both septic and non-septic ICU) and have experience conducting immunotherapeutic trials on humans. | Collaborative seamless investigation and trials that actively accomplishes stated goals as well as results in "win/win" research for all PI's and patients. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Sanjay Purushotham | University of Maryland Baltimore County | psanjay@umbc.edu | Baltimore, MD | Trustworthy AI/ML for ICU time series data analysis; Federated Learning for healthcare data; human digital twins research; | Clinicians; digital twin experts | TA2: Model - Digital Twin Generator |
| Wolfgang Losert | University of Maryland College Park | wlosert@umd.edu | College Park, MD | Generation of dynamic twin with limited training data. Focus on (1) rapid anomaly detection in multimodal data based on limited training data, and (2) predicting dynamics. | Seeking to partner with experts in measurement | TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Cyrus Mintz | University of Maryland School of Medicine | DMintz@som.umaryland.edu | Baltimore, MD | Microbiome and ICU | Digital Twin Predictive Modeling of Immune Therapy and Respone | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Arvind Rao | University of Michigan Ann Arbor | ukarvind@umich.edu | Ann Arbor, MI | We develop computational frameworks for modeling and controlling complex biological systems using multimodal data, digital twins, and trajectory-based state estimation. Our work focuses on immune dynamics, disease progression, and intervention optimization through interpretable AI, systems biology, and decision intelligence methods to enable predictive and personalized healthcare. | We seek partners with expertise in critical care, systems immunology, immune biomarker measurement, and clinical data platforms to support real-time immune state characterization, model validation, and intervention testing. We welcome collaborators with ICU cohorts, translational capabilities, and clinical deployment pathways to enable integrated measurement, modeling, and immune reprogramming solutions. | TA3: Modulate - Rational Immune Reprogrammer, TA2: Model - Digital Twin Generator |
| Jacob Brenner | University of Pennsylvania | jacob.brenner@pennmedicine.upenn.edu | Philadelphia, PA | Our University of Pennsylvania (Penn) team includes: critical care physicians who have the among the largest biobanks of samples from critically ill patients (and still enrolling); a leader in developing lipid nanoparticles (LNP) therapies to treat acute critical illnesses; a leader in computational modeling of signaling networks and "digital twins". | companies that could turn our findings into therapeutics | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| James McGrath | University of Rochester | james.mcgrath@rochester.edu | Rochester, NY | The McGrath Lab at the University of Rochester develops microphysiological systems (MPS) built on our ultrathin silicon membrane platform (µSiM) for modeling vascular barriers, including the blood-brain barrier and inflamed endothelium. Current programs focus on label-free neutrophil transmigration assays, endothelial barrier function under inflammatory challenge, and cytokine release syndrome modeling. We have validated µSiM for functional immune readouts relevant to sepsis pathophysiology. | We seek partners with (1) clinical sepsis cohort access and biobanked samples for model training, (2) computational/ML expertise in digital twin development for immune dynamics, (3) complementary biomarker detection platforms (e.g., single-molecule or deformability cytometry) that pair with our functional tissue-chip readouts, and (4) experience with ARPA-H milestone-driven contract structures. We bring a validated in vitro platform for neutrophil trafficking and barrier assessment. | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Anthony Pietropaoli | University of Rochester Medical Center | anthony_pietropaoli@urmc.rochester.edu | Rochester, NY | Our team unites expertise in critical care, infectious disease, inflammatory biology, complex in vitro models, high-sensitivity biomarker detection, systems biology, mechanistic dynamic modeling, and machine learning. We measure (TA1) novel biomarkers in patient samples. Predictive modeling (TA2) will combine these biomarkers with comprehensive EHR data, producing an adaptive digital twin, permitting real-time treatment simulations that modulate (TA3) patient care and clinical trials. | We seek partners to develop a commercially deployable platform that will “productize” our digital twins. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Anthony Pietropaoli | University of Rochester Medical Center | anthony_pietropaoli@urmc.rochester.edu | Rochester, NY | Our team unites expertise in critical care, infectious disease, inflammatory biology, complex in vitro models, high-sensitivity biomarker detection, systems biology, mechanistic dynamic modeling, and machine learning. We measure (TA1) novel biomarkers in patient samples. Predictive modeling (TA2) will combine these biomarkers with comprehensive EHR data, producing an adaptive digital twin, permitting real-time treatment simulations that modulate (TA3) patient care and clinical trials. | We seek partners to develop a commercially deployable platform that will “productize” our digital twins. | TA1: Measure - Dynamic Immune Descriptor, TA2: Model - Digital Twin Generator |
| My Helms | University of Utah School of Medicine | my.helms@hsc.utah.edu | Salt Lake City, UT | Focusing on lung epithelial cell's role in triggering innate immune response and looking at therapeutic intervention for newborn lung injury using preclinical animal model systems and primary human lung cells. | computational modeling | TA1: Measure - Dynamic Immune Descriptor, AP1: Critical Illness Clinical Data & Analysis Platform |
| Richard Novak | Unravel Biosciences, Inc. | richard.novak@unravel.bio | Medford, MA | Unravel leverages its proprietary BioNAV platform and primary transcriptomics data to create Living Molecular Twins of real patients that can be used to predict therapeutic response. This enables target and drug discovery, preclinical screening, patient stratification, and clinical validation to find treatments for complex diseases using a systematic, data-driven approach called Predictable Medicine. This has been used for personalized medicine of over 500 unique, complex patients. | Emergency care partners willing to implement non-invasive sample collection strategies an eventually participate in clinical studies of immune modulators output by our platform. | TA2: Model - Digital Twin Generator, TA3: Modulate - Rational Immune Reprogrammer |
| Andrew Meyer | UT Health San Antonio/USAISR | meyera@uthscsa.edu | San Antonio, TX | We conduct translational and clinical research in trauma and critical care focused on immune–coagulation interactions, extracorporeal life support (ECMO), and organ failure. Our work integrates in vitro flow models, small and large animal trauma models biospecimen analysis, computational modeling, and early-phase clinical studies to define mechanistic drivers of hemorrhage, inflammation, and multi-organ dysfunction and to develop deployable, data-driven therapeutic strategies. | We seek partners with expertise in systems immunology, high-throughput biomarker platforms, AI-driven predictive modeling, and interoperable data systems capable of real-time deployment. Experience in critical care datasets, point-of-care diagnostics, regulatory strategy, and scalable device or software development is highly valued. | AP3: Critical Illness Clinical Trials Platform, AP1: Critical Illness Clinical Data & Analysis Platform |
| David Voros | Verily | dpvoros@verily.com | South San Fransisco, CA | Verily’s mission is to make healthcare more predictive, preventative, and precise. We design, deploy, and scale AI models and agents, developed with clinical input, for research and care workflows. Verily’s interdisciplinary team spanning clinicians, informaticists, world class engineers, data scientists, and regulatory experts strive to ensure AI solutions are built for safety and trustworthiness from concept to secure deployment. | Verily is open to teaming partners to compliment any domain specific methods. | AP1: Critical Illness Clinical Data & Analysis Platform |
| Jyotika Varshney | Verisim Life Inc. | jo.varshney@verisimlife.com | San Francisco, CA | VeriSIM Life builds immune digital twins that mechanistically model host response, inflammation cascades, and organ failure trajectories in critical illness. By integrating high-frequency ICU data, physics-based models, and multimodal AI, BIOiSIM moves beyond retrospective prediction to simulate forward disease evolution and test intervention strategies in silico, enabling proactive, physiology grounded decision support at the bedside. | We seek ICU, health system, and translational collaborators with access to high resolution longitudinal immune profiling, multi omics, and real world clinical data. Ideal partners will co develop and prospectively validate deployable immune digital twin workflows, integrate experimental platforms where relevant, and align on regulatory grade decision support tools for critical care settings. | TA2: Model - Digital Twin Generator |
| Xuan Wang | Virginia Tech | xuanw@vt.edu | Blacksburg, VA | Multi-Modal Science Foundation Models (FMs): Systematic integration of multi-modal FMs Interpretability, explainability, and causal inference of science FMs Text data, multi-omics data, brain signal data, … Complex Reasoning and Planning with Language Model Agents: Complex reasoning with large language models (multi-hop, long-context, …) Multi-agent large language models for reasoning and planning Efficient small language models for reasoning and planning | Looking to join a team led by clinical experts | TA2: Model - Digital Twin Generator |
| Matthew Lawrence | Virscio | mlawrence@virscio.com | New Haven, CT | Virscio applies nonhuman primate and ex vivo modeling to establish predictive test systems to decipher pathophysiology and screen candidates for therapeutic effect, enabled by medical imaging, clinical and anatomic pathology, immune and multiomic profiling, and physiologic endpoints. We define new translational biomarkers and apply to robust, dynamic interrogation of disease process and tissue pharmacodynamics of novel interventions. | Virscio is looking to expand on existing partnerships to harness in silico and molecular tools, enabled by digital twins, to accelerate the development of the most predictive possible in vivo critical care models that are both animal resource efficient and direct paths to clinical realization. We seek to iteratively modulate pathways to confirm key mediators of inflammation associated with critical illness to confirm targets and screen candidate interventions with IND-enabling studies. | TA1: Measure - Dynamic Immune Descriptor, TA3: Modulate - Rational Immune Reprogrammer |
| Isaiah Turnbull | Washington University in Saint Louis | iturnbull@wustl.edu | Saint Louis, MO | My research group integrates molecular and functional immunophenotyping to elucidate the mechanisms driving immune dysfunction in critical illness, including sepsis and trauma. We have established a comprehensive infrastructure for patient recruitment, biospecimen biobanking, and the execution of high-throughput assays capable of identifying signaling abnormalities that underlie critical illness–induced deficits in immune cell function. | Expertise in transcriptomics and computational modeling. Clinical partners with access to additional subjects. | AP1: Critical Illness Clinical Data & Analysis Platform |
| Rajat Dhar | Washington University in St. Louis School of Medicine | dharr@wustl.edu | Saint Louis, MO | Evaluating non-invasive transcutaneous vagal nerve stimulation to modulate the immune system after brain injury | Expertise in digital twins for models of brain injury | TA3: Modulate - Rational Immune Reprogrammer, TA1: Measure - Dynamic Immune Descriptor |
| Michael McLoughlin | Zeteo Tech | mike.mcloughlin@zeteotech.com | Sykesville, MD | AImmuneX® is a MALDI-MS based, highly multiplexed platform to measure dynamic host response to infection from various sample types such as breath, fingertip blood and plasma. Analysis of host immune responses and pathogen from breath has diagnosed presymptomatic infection, differentiated viral from bacterial infection, identified antimicrobial resistance and measures dynamic response to therapeutic intervention. AImmuneX is a very low-cost and rapid (<2hrs) platform that meets TA1 objectives. | We seek TA2/TA3 partners that can utilize AImmuneX to obtain the functional readout of innate immune effectors required to drive the development of patient specific digital twins and utilize these quantitative measures of immune response to develop new intervention strategies. | TA1: Measure - Dynamic Immune Descriptor |